Design and Synthesis of Novel α_{1a} Adrenoceptor-Selective Antagonists. 2. **Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker** and 4-Methoxycarbonyl-4-phenylpiperidine Moiety^{1,2}

T. G. Murali Dhar,^{†,⊥} Dhanapalan Nagarathnam,[†] Mohammad R. Marzabadi,^{*,†} Bharat Lagu,[†] Wai C. Wong,[†] George Chiu,[†] Sriram Tyagarajan,[†] Shou Wu Miao,[†] Fengqi Zhang,[†] Wanying Sun,[†] Dake Tian,[†] Quanrong Shen,[†] Jack Zhang,[†] John M. Wetzel,[†] Carlos Forray,[‡] Raymond S. L. Chang,[§] Theodore P. Broten,[§] Terry W. Schorn,[§] Tsing Bao Chen,[§] Stacy O'Malley,[§] Richard Řansom,[§] Kathryn Schneck,[§] Robert Bendesky,[§] Charles M. Harrell,[§] Kamlesh P. Vyas," Kanyin Zhang," John Gilbert," Douglas J. Pettibone,[§] Michael A. Patane,[¬] Mark G. Bock,[¬] Roger M. Freidinger,[∇] and Charles Gluchowski[†]

Departments of Chemistry and Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, New Jersey 07652, and Departments of Pharmacology, Drug Metabolism, and Medicinal Chemistry, Merck & Company, Inc., West Point, Pennsylvania 19486

Received April 23, 1999

We have previously described compound **1a** as a high-affinity subtype selective α_{1a} antagonist. In vitro and in vivo evaluation of compound 1a showed its major metabolite to be a μ -opioid agonist, 4-methoxycarbonyl-4-phenylpiperidine (3). Several dihydropyrimidinone analogues were synthesized with the goal of either minimizing the formation of $\mathbf{3}$ by modification of the linker or finding alternative piperidine moieties which when cleaved as a consequence of metabolism would not give rise to μ -opioid activity. Modification of the linker gave several compounds with good α_{1a} binding affinity ($K_i = < 1$ nM) and selectivity (>300-fold over α_{1b} and α_{1d}). In vitro analysis in the microsomal assay revealed these modifications did not significantly affect N-dealkylation and the formation of the piperidine 3. The second approach, however, yielded several piperidine replacements for **3**, which did not show significant μ -opioid activity. Several of these compounds maintained good affinity at the α_{1a} adrenoceptor and selectivity over α_{1b} and α_{1d} . For example, the piperidine fragments of (+)-73 and (+)-83, viz. 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the μ -opioid receptor (IC₅₀ > 30 μ M vs 3 μ M for **3**). Compounds (+)-**73** and (+)-**83** were subjected to detailed in vitro and in vivo characterization. Both these compounds, in addition to their excellent selectivity (>880-fold) over α_{1b} and α_{1d} , also showed good selectivity over several other recombinant human G-protein coupled receptors. Compounds (+)-73 and (+)-83 showed good functional potency in isolated human prostate tissues, with $K_{\rm b}$ s comparable to their in vitro α_{1a} binding data. In addition, compound (+)-73 also exhibited good uroselectivity (DBP $K_b/$ IUP $K_b > 20$ -fold) in the in vivo experiments in dogs, similar to **1a**.

Introduction

We have been interested³⁻⁵ in developing α_{1a} adrenoceptor⁶-selective antagonists due to their potential to provide significant improvement in the treatment of benign prostatic hyperplasia (BPH)⁷⁻⁹ over the clinically used nonselective α_1 adrenoceptor antagonists such as terazosin¹⁰ and doxazosin.¹¹ In the preceding article,² we presented the biological rationale for design of α_{1a} adrenoceptor-selective antagonists. Therein, we presented the design and synthesis of several dihydropyrimidinone derivatives as potent α_{1a} adrenoceptorselective antagonists. We identified compound 1a as the lead candidate with excellent functional potency in the isolated human prostate tissue and presented data that showed good uroselectivity in dogs.

In vitro evaluation of **1a** in human liver microsomes and in vivo evaluation in rat and dog defined the metabolic pathway depicted in Chart 1, with the predominant (>50%) formation of 2 and 4-methoxycarbonyl-4-phenylpiperidine (3). Compound 2 was found to be devoid of α_{1a} antagonist activity and showed negligible cross-reactivity at several other G-protein coupled receptors and the L-type calcium channel. Metabolite **3**, however, was found to be a μ -opioid agonist (IC₅₀ = 3 μ M) and is a close analogue of the μ -opioid agonist meperidine (IC₅₀ = 1.1μ M).¹² Hydrolysis of the piperidine-4-methoxycarbonyl ester to form the carboxylic acid **4** has been shown to occur. Meperidine is well-known for the undesirable narcotic and sedative properties. In addition, 3 showed a long plasma half-life (>12 h) in rats and dogs that raised concerns that this metabolite 3 may lead to opioid agonist liabilities on chronic administration of **1a**. These findings prompted us to search for compounds devoid of this potential liability.

We set out to attain these goals by two major approaches: (i) minimize the metabolic formation of 4-methoxycarbonyl-4-phenylpiperidine (3) by modification of the linker and (ii) replace this piperidine portion with other piperidines that do not have the μ -opioid

 [†] Department of Chemistry, Synaptic Pharmaceutical Corp.
 [‡] Department of Pharmacology, Synaptic Pharmaceutical Corp.
 [§] Department of Pharmacology, Merck & Co.
 [॥] Department of Drug Metabolism, Merck & Co.
 [⊽] Department of Medicinal Chemistry, Merck & Co.
 [⊥] Current address: Bristol Myers Squibb Corp., Princeton, NJ.

13, 14 : $R = NH_2$

vi

Chart 1



^{*a*} (i) EtOH, reflux; (ii) HPLC separation of enantiomers; (iii) RaNi (H₂); (iv) 6 N HCl; (v) H₂, Pd-C, MeOH/water; (vi) EDC, NMM, NH₄OH, CH₂Cl₂.





Scheme 3^a



^{*a*} (i) PTS, toluene; (ii) NaBH₃CN; (iii) H₂, Pd-C, MeOH/water; (iv) Cu₂O, HOAc, BF₃·OEt₂, THF; (v) HPLC separation; (vi) LiHMDS, 4-nitrophenyl chloroformate; (vii) HCl; (viii) H₂, Pd-C, MeOH/water; (ix) EDC, NMM, NH₄OH, CH₂Cl₂.

agonist activity. The results from these studies are summarized here.

Chemistry

Schemes 1-3 describe the syntheses of compounds with linker modifications. Piperidine **3** was reacted with crotononitrile (**5**), and the resultant racemic nitrile **6** was resolved via chiral HPLC (Scheme 1). The individual enantiomers were then reduced to the enantiomeric amine **7** by Raney nickel-catalyzed hydrogenation. Independently, these amines were reacted with the (4nitrophenyl)carbamoyldihydropyrimidine **8**² and subsequently treated with HCl to afford the benzyl esters **9** and **10**. These compounds on hydrogenation gave the carboxylic acids **11** and **12**, which upon coupling with ammonia gave products **13** and **14**.

Reaction of dihydropyrimidine **15** with 5-bromo-1chloropentane (**16**) gave the chloride **17** which on reaction with piperidine **3** gave **18** (Scheme 2). Alkylation of dihydropyrimidine **15** with benzyl 2-bromoacetate gave **19**, which upon hydrogenation provided the carboxylic acid **20**. The 2-aminoethylpiperidine side chain **21** was prepared by reaction of piperidine **3** with 2-bromoethylamine. Subsequently, the carboxylic acid **20** was coupled with amine **21** in the presence of DMAP and EDC to provide **22**.

The piperidinylpiperidine derivative **24** was obtained by condensation of *N*-benzyl-4-piperidone (**23**) with piperidine **3** and subsequent reduction of the intermediate with NaBH₃CN (Scheme 3). Hydrogenation of **24** with 10% Pd-C gave the piperidinylpiperidine **25**, which on reaction with dihydropyrimidine **26**² and treatment with HCl gave **27**. The racemic dihydropyrimidinone **32** was prepared by reaction of 3,4-difluorobenzaldehyde (**30**) with methyl 4-methoxyacetoacetate (**28**) and urea (**29**) in the presence of Cu₂O, boron

Scheme 4



trifluoride-etherate, and acetic acid.¹³ Compound **32** was resolved using a chiral HPLC column. The (+) enantiomer of **32** was reacted with LiHMDS followed by treatment with 4-nitrophenyl chloroformate to give the dihydropyrimidine carbamate ester **34**. Compound **34**, upon reaction with amine **25**, gave product **36**. The 3,4,5-trifluorophenyl-substituted dihydropyrimidine analogue **37** was prepared using a similar procedure. Compound **41** was prepared from the dihydropyrimidine benzyl ester intermediate **38** and amine **25** following a similar sequence of reactions described for **13** and **14** in Scheme 1.

Schemes 4–7 describe the syntheses of compounds with piperidine replacements. The spirocyclic piperidines $42a-42g^{14,15}$ were alkylated with 1-N-(*tert*-butoxycarbonyl)-3-bromopropylamine, and the resulting BOC-protected aminopiperidines 44 were treated with TFA to give the 3-aminopropylpiperidines 45a-45g (Scheme 4). These amines, upon reaction with the pyrimidine **26** followed by treatment with HCl, gave **46–52**. Using a similar procedure, compound **56** was synthesized from 26 and 3-(4,4-diphenylpiperidin-1-yl)propylamine.³ The diarylpiperidines **54a**–**54d** were synthesized via a Friedel-Crafts reaction of 4-hydroxy-4-arylpiperidines **53a**–**53d** with substituted benzenes. Reaction of **26** with HCl followed by treatment with 3-bromopropylamine gave the 3-bromopropylcarbamoyldihydropyrimidine 55. The diarylpiperidines 54a-54d were reacted with the bromide 55 to afford products 57-60.

Scheme **5** summarizes the synthesis of a series of compounds with modifications at the C-4 methoxycar-

Scheme 5^a



^a (i) K₂CO₃; (ii) NaH, Ac₂O; (iii) H₂, 10% Pd-C; (iv) HCl.

bonyl piperidine position. Reaction of 4-hydroxy-4phenylpiperidine (**61**) with 1-*N*-(benzyloxycarbonyl)-3bromopropylamine (**62**) gave **63** which on acetylation with acetic anhydride followed by hydrogenolysis gave **65a**. Side chains **65b**-**65e** were synthesized following reported methods.^{3,5} Reaction of **26** with amines **65a**-**65e** followed by treatment with HCl gave **66**-**70**.

The synthesis of **73** is described in Scheme 6. Dihydropyrimidine **38**² was reacted with 3-(4-cyano-4-phenylpiperidin-1-yl)propylamine (**65d**) and subsequently treated with HCl to afford the benzyl ester **71**, which upon catalytic hydrogenation gave carboxylic acid **72**. Scheme 6^a



^a (i) Amine 65d; (ii) HCl; (iii) H₂, Pd-C, MeOH/water; (iv) EDC, NMM, NH₄OH, CH₂Cl₂.





^{*a*} (i) NaH; (ii) TFA; (iii) (a) BOC-NH-CH₂CH₂CH₂Br, K_2CO_3 , KI, acetone, (b) TFA; or (a) 3-bromopropylphthalimide, K_2CO_3 , KI, DMF, (b) H_2N-NH_2 , methanol.

Acid **72** was then converted to the amide **73** by reaction with ammonia in the presence of EDC and NMM.

Compound **79** was synthesized by the reaction of pyrimidinone **34**² with amine **65d**. The 4-aryl-4-cyanopiperidines **76a**-**76c** were synthesized from the corresponding 4-arylacetonitriles **75a**-**75c** by dialkylation with *N*-tert-butoxycarbonyl-bis(2-chloroethyl)amine (**74**) followed by treatment with TFA. The 3-aminopropyl moiety was introduced as described above or by reaction with 3-bromopropylphthalimide and subsequent treatment with hydrazine. Side chains **78a**-**78c** were reacted with the pyrimidinone **34** to provide compounds **80**-**82**. Compound **83** was synthesized by reaction of **34** with 3-(4-phenyl-4-methylpiperidin-1-yl)propylamine (**65e**).

Results and Discussion

Initially, we used compound **1a**, its 2,4-difluoro analogue **1b**, or **1c** (see Chart 1) for the modifications of the linker and the piperidine. Later, we also made additional modifications on the dihydropyrimidinone moiety. In the first part of the discussion we present the structure–activity relationship (SAR) with respect to the α_{1a} binding affinity and selectivity of the resultant compounds. Subsequent discussions focus on the opioid activity of putative piperidine metabolites and additional in vitro and in vivo characterization.

Effect of Modification of the Linker on Binding Affinities. Introduction of a methyl group on the linker carbon adjacent to the piperidine nitrogen in order to

minimize the N-dealkylation resulted in the two diastereomers 13 and 14 (Scheme 1). Among these, 13 showed higher binding affinity for the α_{1a} adrenoceptor than 14. Compound 13 was 20 times weaker than 1a but showed >300-fold subtype selectivity (Table 1). Changing the amide linker (CONHCH₂CH₂CH₂) between dihydropyrimidinone and piperidine moieties to an all carbon alkyl chain (CH₂CH₂CH₂CH₂CH₂CH₂) gave compound 18. Rearrangement of the CONHCH₂CH₂CH₂ linker to CH₂CONHCH₂CH₂ gave 22 which reduced the distance between the two nitrogens by a methylene unit, while keeping the number of bonds between the dihydropyrimidinone and the piperidine constant.^{3,4} Both compounds 18 and 22 showed good α_{1a} binding and selectivity profile ($K_i = 0.1-0.2$ nM, >1200-fold). In another approach, we conformationally restricted the linker with a piperidinyl moiety to minimize the Ndealkylation. The initial compound 27 in this series exhibited a significantly lower α_{1a} binding affinity (19 nM vs 0.1 nM for 1c). However, when the dihydropyrimidinone C-4 methyl (R₂) group was changed to a 2-methoxymethyl (**36**) the α_{1a} affinity improved ($K_i = 7.5$ nM). Further improvement was seen ($K_i = 1.7$ nM) when a third fluorine was added on the C-6 phenyl ring to yield the dihydropyrimidinone **37** ($K_i = 1.7$ nM, >1800-fold). We also synthesized a close analogue of our earlier lead compound **1b** with this piperidylpiperidine modification (41); however, the compound showed a comparatively lower α_{1a} affinity (81 nM).

Effect of Spirocyclic Piperidine Modifications

Table 1. α1 Binding Profile of Linker-Modified Dihydropyrimidinones



					$K_{\rm i}$ (nM) ^a		
compd	R′	R″	R‴	Х	α_{1a}	α_{1b}	α_{1d}
prazosin					0.6	0.6	0.3
SNAP 6201 (1a)	H_2N	Et	$3, 4-F_2$	CO-NH-(CH ₂) ₃ -	0.2	250	340
1b	H_2N	Et	$2, 4-F_2$	CO-NH-(CH ₂) ₃ -	0.2	220	340
1c	MeO	Me	$3, 4-F_2$	CO-NH-(CH ₂) ₃ -	0.1	45	140
13	H_2N	Et	$3, 4-F_2$	CO-NH-(CH ₂) ₂ -(CHMe)-	4.2	1480	2100
14	H_2N	Et	$3, 4-F_2$	CO-NH-(CH ₂) ₂ -(CHMe)-	58	1450	2260
18	MeO	Me	$3, 4-F_2$	-(CH ₂) ₅ -	0.1	140	150
22	MeO	Me	$3, 4-F_2$	-CH ₂ -CO-NH-(CH ₂) ₂ -	0.2	1050	610
27	MeO	Me	$3, 4-F_2$	Q	19	1940	2260
36	MeO	MeOCH ₂	3,4-F ₂		7.5	2630	5280
37	MeO	MeOCH ₂	3,4,5-F ₃	O N	1.7	3130	5370
41	H2N	Et	2,4-F ₂	O N	81	15500	14700

^{*a*} All K_i values are $\pm 5\%$ SE or less for $n \ge 2$. In the case of n = 2, both K_i values were within 2-fold of each other and the value shown is the average of the two values.

on Binding Affinities. The spirocyclic piperidine analogues were designed to avoid the formation of the piperidine-4-carboxylic acid derivatives such as 4 and to obtain piperidines with minimal μ -opioid activity. The variations included systematic modification of the piperidine 4-phenyl and 4-methoxycarbonyl moieties into lactones, ethers, and carbocycles (Table 2). The 6-5spirocyclic lactone derivative 46 showed a 40-fold lower α_{1a} binding affinity (K_i 4.5 nM vs 0.1 nM for 1c), and the reverse lactone (COO vs OCO) analogue 47 exhibited similar α_{1a} affinity (7.9 nM). The 6–5 spirocyclic ether (48) and the indane (49) analogues, however, exhibited improved binding affinity ($K_i = 0.3$ and 1.1 nM) and selectivity (>200-fold) for the α_{1a} adrenoceptor. The corresponding 6-6 spirocyclic piperidine analogues 50–52 showed significant improvement in the α_{1a} binding and selectivity relative to their five-membered counterparts 47-49. However, these compounds showed significant cross-reactivity at either the α_2 receptor (e.g. **46** \geq 26-fold selectivity over α_{2a} , α_{2c}) or histamine receptor (e.g. $46 \ge 27$ -fold selectivity over H₁) (Table 2).

Effect of Diarylpiperidine Modifications on Binding Affinities. When tested at the μ -opioid receptor, 4,4-diphenylpiperidine (**54a**) showed an IC₅₀ > 17 μ M. This result suggested that we could use diarylpiperidines as replacements for **3** and thereby minimize the μ -opioid liability. Substitution of the piperidine moiety of **1c** with 4,4-diphenylpiperidine resulted in compound **56** with good α_{1a} affinity ($K_i = 1.85$ nM); however, it showed only ~20-fold selectivity over the α_{1b} subtype (Table 3). Further modification of the phenyl rings with a bis-4-chloro substitution (**54b**) resulted in lower affinity (**57**, $K_i = 6.9$ nM); however, a bis-4-fluoro substitution (**54c**) improved the α_{1a} binding as well as the selectivity (**58**, $K_i = 0.16$ nM, >125-fold). A 2- and 4'-dimethyl substitution (**54d**) improved the α_{1a} affinity of the analogue **59** to $K_i = 0.06$ nM and the subtype selectivity to over 1300-fold.

The μ -opioid activities of the diarylpiperidines are summarized in Table 4. We identified 4,4-bis(3,5-dimethylphenyl)piperidine (**54e**) to have weak activity at the μ -opioid receptor (IC₅₀ = 27 μ M). Its dihydropyrimidinone derivative **60** showed 4.6 nM affinity at the α_{1a} adrenoceptor with >186-fold over α_{1b} and α_{1d} adrenoceptors.

Effect of Modifications of the 4-Methoxycarbonyl Moiety of Piperidine on Binding Affinities. In this section, we replaced the 4-methoxycarbonyl group of the piperidine with acetoxy, methoxy, cyano, hydrogen, and methyl groups (Table 5). The reverse ester derivative **66** showed 3-fold less affinity ($K_i = 0.3$ nM vs 0.1 nM) than its methoxycarbonyl analogue 1c but showed improved subtype selectivity (>2000-fold for both α_{1b} and α_{1d}). Replacement of the 4-methoxycarbonyl group with methoxy (67) resulted in 10-fold lower α_{1a} affinity but retained good selectivity over α_{1b} and α_{1d} (>250-fold). Interestingly, the analogue of **1c** unsubstituted at position 4 (68) retained good affinity (K_i = 0.21 nM) and selectivity (>170-fold). The 4-cyanosubstituted compound 69 exhibited a significantly reduced affinity ($K_i = 3.2$ nM) and subtype selectivity



^{*a*} All K_i values are $\pm 5\%$ SE or less for n > 2. In the case of n = 2, both K_i values were within 2-fold of each other and the value shown is the average of the two values.

(>70-fold) at the α_{1a} adrenoceptor. Substitution with a methyl group, however, provided compound **70** with excellent (>540-fold) α_1 adrenoceptor subtype selectivity. Synthesis of a close analogue of **1b** with 4-cyano-4-phenylpiperidine resulted in compound (+)-**73**, which showed good α_{1a} binding ($K_i = 0.67$ nM) affinity and >900-fold subtype selectivity.

Synthesis of additional analogues of **69** and **70** with a C-4 methoxymethyl group instead of a methyl group resulted in compounds **79** and **83** (Table 6), respectively, with excellent α_{1a} adrenoceptor binding profile. Further modification of the phenyl group of 4-phenyl-4-cyanopiperidine with a fluoro substitution provided several compounds (**80–82**) with good α_{1a} affinity, with the 4-fluoro analogue **82** being the best ($K_i = 0.06$ nM) among these compounds (Table 6).

Metabolism and Opioid Activity. We tested linkermodified analogues **13**, **18**, **22**, and **37** in the isolated rat/human liver microsomes and/or for their oral bioavailability and half-life in rats. The PK results revealed no improvement in half-life or bioavailability as compared to **1a**-**1c**. The fact that the half-life and/or bioavailability of linker-modified analogues were not

Table 3. α_1 Binding Profile of Diarylpiperidine-Substituted Dihydropyrimidinones



compd	R_1	R_2	α_{1a}	α_{1b}	α_{1d}
1c			0.1	45	140
56	Н	Н	1.9	36	190
57	4-Cl	4-Cl	6.9	84	560
58	4-F	4-F	0.2	20	120
59	$2-CH_3$	$4-CH_3$	0.06	80	250
60	3,5-dimethyl	3,5-dimethyl	4.6	860	750

^{*a*} All K_i values are $\pm 5\%$ SE or less for n > 2. In the case of n = 2, both K_i values were within 2-fold of each other and the value shown is the average of the two values.

improved suggested that either the levels of the piperidine metabolite were not significantly changed or the presence of a new linker had changed the route of the metabolism. In either case, the poor PK performance of the analogues precluded any further work in this area.

On the other hand, in the second approach several final products and their piperidines showed decreased μ -opioid activity. For example, compounds (+)-**73** and (+)-**83** and their piperidine fragments, 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the opioid receptor (IC₅₀ > 30 μ M vs 3 μ M for **3**).

In Vitro and in Vivo Properties of (+)-73 and (+)-83. Compounds (+)-73 and (+)-83 were characterized in further in vitro and in vivo assays. Table 7 summarizes the in vivo properties of (+)-73 and (+)-83 in comparison to SNAP 6201 and terazosin. Both (+)-73 and (+)-83, in addition to their excellent selectivities over α_{1b} and α_{1d} , were also found to be selective over several recombinant human G-protein coupled receptors. The panel of G-protein coupled receptors included α_{2a} , α_{2b} , α_{2c} adrenoceptors, histamine-H₁, and -H₂, 5HT-1A, -1B, -1D, and -2A, and dopamine (D₁, D₃, D₅) receptors and also at the rat L-type calcium channel, with selectivities ranging from 280-fold to greater than 1000-fold.

Compounds (+)-**73** and (+)-**83** showed good potencies with respect to the prostate in rat, dog, and human tissues, whereas terazosin showed good potencies in the prostate as well as the aorta (19 nM). In addition, in the phenylephrine-stimulated urethral pressure experiments in dog, compound (+)-**73** showed good potency (IUP $K_{\rm b} = 14 \,\mu g/\text{kg}$) and uroselectivity (DBP $K_{\rm b}/\text{IUP } K_{\rm b} = >20$) compared to the poor selectivity seen for terazosin (DBP $K_{\rm b}/\text{IUP } K_{\rm b} = \sim1$).

The pharmacokinetic profile of (+)-**73** was determined in male Sprague–Dawley rats and in male beagle dogs at 1 mg/kg iv and 3 mg/kg oral dose with quantification via HPLC. The results showed 8% oral bioavailability in rats with 35-min $t_{1/2}$ and 19% oral bioavailability and 138-min $t_{1/2}$ in dogs (Table 7). Using the HPLC quantification assay, (+)-**83** in the dog showed longer plasma

Table 4. Effect of 4,4'-Diaryl Substitution on Opioid Activity (IC₅₀, μ M) of Selected Piperidines^a

compd	R ₁	R_2	opioid binding, [³ H]DAMGO (μ M)
normeperidine	phenyl	carbethoxy	1.1
54a	phenyl	phenyl	17
54d	2-methylphenyl	4-methylphenyl	6
54e	3,5-dimethylphenyl	3,5-dimethylphenyl	27

^{*a*} All IC₅₀ values are \pm 30% SE or less for n > 2. In the case of n = 2, both IC₅₀ values were within 2-fold of each other and the value shown is the average of the two values.





					$K_{\rm i}$ (nM) ^a		
compd	R′	R‴	R‴	R	α_{1a}	α_{1b}	α_{1d}
1c	MeO	Me	$3, 4-F_2$	CO ₂ Me	0.1	45	140
66	MeO	Me	$3, 4-F_2$	OCOMe	0.3	700	780
67	MeO	Me	$3, 4-F_2$	OMe	1	250	370
68	MeO	Me	$3, 4-F_2$	Н	0.2	36	150
69	MeO	Me	$3, 4-F_2$	CN	3.2	340	230
70	MeO	Me	$3, 4-F_2$	Me	0.5	270	480
(+)-73	H_2N	Et	$2,4-F_2$	CN	0.7	610	1280

^{*a*} All K_i values are $\pm 5\%$ SE or less for n > 2. In the case of n = 2, both K_i values were within 2-fold of each other and the value shown is the average of the two values.

Table 6. α_{1a} Binding Profile of Dihydropyrimidinones **79–83**



R_1	R	α_{1a}	α_{1b}	α_{1d}
		0.1	45	140
CN	Н	0.1	130	260
CN	2-F	5.2	730	930
CN	3-F	0.2	150	180
CN	4-F	0.06	30	110
Me	Н	0.5	440	640
	R ₁ CN CN CN CN Me	R1 R CN H CN 2-F CN 3-F CN 4-F Me H	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$

^{*a*} All K_i values are $\pm 5\%$ SE or less for n > 2. In the case of n = 2, both K_i values were within 2-fold of each other and the value shown is the average of the two values.

half-life (6.5 h vs 2.5 h for **1a**). Compound (+)-**83** showed 23% bioavailability and a half-life of 24 min in the rat (Table 7).

Summary

A series of dihydropyrimidinone analogues were synthesized with the goal of either minimizing the formation of meperidine-like metabolite **3** or finding replacement moieties that were devoid of the μ -opioid agonist activity. The initial approach involved the introduction of a methyl group on the linker carbon adjacent to the piperidine, all-alkyl carbon linker, and conformational restriction of the linker into a piperidine. Several compounds with good α_{1a} binding affinity ($K_i =$

<1 nM) and selectivity (>300-fold over α_{1b} and α_{1d}) were obtained. In vitro analysis in the microsomal assay revealed these modifications did not significantly affect *N*-dealkylation and formation of the piperidine **3**. In addition, none of the compounds tested showed significant improvement in the pharmacokinetic profile, compared to **1a**.

In the second approach, however, we successfully identified several piperidines devoid of the μ -opioid activity, as replacements for 3. For example, the piperidine pieces of (+)-73 and (+)-83, viz. 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the μ -opioid receptor (IC₅₀ > 30 μ M vs 3 μ M for 3). Compounds (+)-73 and (+)-83 were subjected to further in vitro and in vivo characterization. Both these compounds, in addition to their excellent selectivity (>880-fold) over α_{1b} and α_{1d} , also showed good selectivity over several recombinant human G-protein coupled receptors. Similar to 1a, compound (+)-73 also exhibited good in vivo functional potency (IUP $K_b = 14$ μ g/kg) in the dogs with a DBP K_b /IUP K_b ratio of >20 versus no selectivity seen for the nonselective α_1 adrenoceptor antagonist terazosin. Compound (+)-83 in the isolated human prostate tissues showed good functional potency comparable to its in vitro binding affinity at the human α_{1a} adrenoceptor ($K_b = 0.66$ nM vs $K_i = 0.14$ nM). Neither (+)-73 nor (+)-83, however, showed significantly improved pharmacokinetic profiles over 1b. Another approach to address the issue of opioid active metabolites is described in the accompanying paper.²⁴

Experimental Section

All protocols for the chemical and biological (in vitro and in vivo) experiments are described in the preceding manuscript.²

(+)-5-Carboxamido-6-(3,4-difluorophenyl)-4-ethyl-1-{*N*-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-2methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (14). (a) 3-(4-Methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropionitrile (6). To a solution of 4-methoxycarbonyl-4-phenylpiperidine (3.48 g, 15.8 mmol) in MeOH (25 mL) was added crotononitrile (5.32 g, 79.0 mmol) and the mixture was heated at reflux temperature for 4 h. Methanol and excess crotononitrile were evaporated and the residue was purified by column chromatography on silica gel (30–100% EtOAc in hexanes). ¹H NMR (CDCl₃): δ 1.16 (d, J = 6.0 Hz, 3 H), 1.86–1.96 (m, 2 H), 2.28–2.60 (m, 6 H), 2.68–2.80 (m, 2 H), 2.96–3,02 (m, 1 H), 3.62 (s, 3 H), 7.20–7.36 (m, 5 H).

(b) 3-(4-Methoxycarbonyl-4-phenylpiperidin-1-yl)-3methylpropionitrile (7). The racemic 3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropionitrile (1.53 g) was resolved by chiral HPLC [Chiralcel OD 20 \times 250 mm #369-703-30604]; λ 254 nm; hexanes/ethanol, 80/20; 80 mg/injection; retention time of the desired enantiomer: 18.18 min. The first desired product was used to synthesize product 13 and the second peak to 14 (31 wt % isolation of the first peak and 35% of the second peak from the racemate).

(c) (+)-5-(Benzyloxycarbonyl)-6-(3,4-difluorophenyl)-4-ethyl-1-{*N*-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahy-

Table 7. Summary and Comparison of in Vitro and in Vivo Properties of (+)-73, (+)-83, SNAP 6201, and Terazosin

assay	agonist/antagonist	(+)- 73	(+)- 83	SNAP 6201	terazosin
K_{i} , α_{1a} human clones (nM)	[³ H]prazosin	0.7	0.5	0.2	6.9
$\alpha_{1b.1d}/\alpha_{1a}$	[³ H]prazosin	>900	>400	>1000	<1.0
$\alpha_{2a,b,c}/\alpha_{1a}$	[³ H]rauwolscine	>1000	>280	>1000	<10.0
$K_{\rm b}$ rat prostate (nM)	phenylephrine	2.2	0.4	0.5	25
$K_{\rm b}$ rat aorta (nM)	norepinephrine	>1000	ND	>1000	19
$K_{\rm b}$ human prostate (nM)	A-61603	ND	0.7	0.1	25
AD_{50} rat prostate ($\mu g/kg$)	phenylephrine	18	69	20	52
duration of action rat (h)	A-61603	1.5	2	>4	3
$IUP^{a} K_{b}/DBP^{b} K_{b}$ (dog)	phenylephrine	>20	ND	>30	1
$K_{\rm b}$ (IUP) ^a dog ($\mu g/kg$)	phenylephrine	14.2	ND	4.2	16.4
$K_{\rm b}$ (DBP) ^b dog (µg/kg)	phenylephrine	>300	ND	187	15.7
opioid K_i (μ M)	1 5 1	51	100	4	
rat F. $t_{1/2}$ (h)		8. ^c 0.4	$23.^{d} 0.4$	$15.^{e} 2.0$	49. 7.5
dog <i>F</i> , $t_{1/2}$ (h)		32, ^f 2.3	ND, 6.5	26, ^e 2.5	-,

^{*a*} Intraurethral pressure. ^{*b*} Diastolic blood pressure. ^{*c*} iv: 1 mg/kg dose, AUC = 49.7 μ mol min/L. po: 3 mg/kg dose, AUC = 62.5 μ mol min/L. ^{*d*} iv: 1 mg/kg dose, AUC = 25.6 μ mol min/L. po: 3 mg/kg dose, AUC = 17.8 μ mol min/L. ^{*e*} See ref 2 for details regarding SNAP 6201 and the in vitro and in vivo protocols for all compounds. ^{*f*} iv: 1 mg/kg dose, AUC = 32 μ mol min/L. po: 3 mg/kg dose, AUC = 30 μ mol min/L. ND, not determined; *F*, bioavailability.

dropyrimidine (9). To a solution of 3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropionitrile (first peak from HPLC, 475 mg, 1.65 mmol) in MeOH (10 mL) was bubbled NH₃ gas for 15 min. Raney Ni (80 mg, prewashed with water and then MeOH) was added to the mixture. The resulting suspension was hydrogenated at 150 psi overnight at room temperature. The suspension was filtered through a pad of Celite and the filtrate was concentrated to leave the amine **7** as an oil (462 mg, 96%), which was used as such in the next step.

To a stirred mixture of (+)-5-(benzyloxycarbonyl)-6-(3,4difluorophenyl)-1,6-dihydro-4-ethyl-2-methoxy-1-[(4-nitrophenyloxy)carbonyl]pyrimidine² (8; 0.87 g, 1.6 mmol) in CH₂Cl₂ (20 mL) was added a solution of 3-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]-3-methylpropylamine (7; 0.70 g, 1.93 mmol) and K_2CO_3 (0.1 g) in THF (25 mL) at room temperature and stirring was continued for 8 h. The suspension was diluted with CH₂Cl₂ (150 mL) and washed with 10% KOH solution (2 imes 10 mL). This solution was mixed with aqueous 10% HCl (2 mL) and stirred for 2 h. The mixture was treated with 10% aqueous KOH solution (10 mL); the organic layer was separated, dried (Na₂SO₄), and concentrated. The residue was purified by column chromatography on silica gel to obtain the product as a white foam (0.52 g), which was used in the next step without further purification. ¹H NMR (CDCl₃): δ 0.92 (d, J = 6.0 Hz, 3 H), 1.21 (t, J = 6.6 Hz, 3 H), 1.49–1.71 (m, 2 H), 1.83-1.87 (m, 2 H), 2.41-2.55 (m, 4 H), 2.65-2.73 (m, 4 H), 3.23-3.40 (m, 2 H), 3.64 (s, 3 H), 3.73 (t, J = 4.5 Hz, 1 H), 5.12 (ABq, $d_A = 5.05$, $d_B = 5.20$, J = 12.3 Hz, 2 H), 6.68 (s, 1 H), 6.98-7.37 (m, 14 H), 8.79 (t, J = 4.2 Hz, 1 H).

(e) (+)-6-(3,4-Difluorophenyl)-4-ethyl-1-{N-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropyl]carboxamido]-2-oxo-1,2,3,6-tetrahydropyrimidine-5-carboxylic Acid (11). A solution of 9 (0.52 g, 0.755 mmol) in MeOH (10 mL) was added to a suspension of 10% Pd-C in MeOH (10 mL) and water (4 mL). The resulting suspension was hydrogenated under 100 psi for 10 h. It was then filtered through a pad of Celite and was washed with MeOH.²⁵ Solvents were evaporated from the filtrate and the residue was dissolved in THF, dried (MgSO₄), and concentrated to obtain the carboxylic acid **11** (0.45 g) as a white solid.

(f) (+)-5-Carboxamido-6-(3,4-difluorophenyl)-4-ethyl-1-{N-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (13). To a solution of 11 in CH₂Cl₂ (40 mL) and NMM (0.30 mL, 2.7 mmol) was added EDC (0.44 g, 1.50 mmol) and the resulting mixture was cooled to 0 °C. Ammonia was bubbled through this solution for 30 min and the resulting suspension was stirred overnight at room temperature. The mixture was washed with saturated aqueous NH₄Cl solution (20 mL) followed by brine (20 mL). The organic layer was dried (Na₂SO₄) and the solvent evaporated. The residue was purified by column chromatography on silica gel using 10% MeOH in CH₂Cl₂ as the eluent to obtain product **13** as a white solid (0.18 g, 40% for two steps). $[\alpha]_D = +115$ (c = 0.25, MeOH). ¹H NMR (CDCl₃): δ 0.93 (d, J = 6.3 Hz, 3 H), 1.26 (t, J = 7.2 Hz, 3 H), 1.49–1.71 (m, 2 H), 1.87–1.94 (m, 2 H), 2.41–2.55 (m, 4 H), 2.65–2.73 (m, 4 H), 3.28–3.42 (m, 2 H), 3.64 (s, 3 H), 3.72 (t, J = 4.5 Hz, 1 H), 5.82 (br s, 2 H), 6.52 (s, 1 H), 7.07–7.36 (m, 8 H), 8.08 (br s, 1 H), 8.81 (t, J = 5.1 Hz, 1 H). It was converted to the HCl salt by treatment with 1 N HCl in ether. Mp: 212–216 °C. Anal. (C₃₂H₃₈N₅O₅F₂Cl·1.1CHCl₃) C, H, N.

(+)-5-Carboxamido-6-(3,4-difluorophenyl)-4-ethyl-1-{*N*-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (14). (a) (+)-5-(Benzyloxycarbonyl)-6-(3,4-difluorophenyl)-4-ethyl-1-{N-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (10). The second HPLC fraction of 3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropionitrile (531 mg, 1.84 mmol) was reduced to the 3-(4methoxycarbonyl-4-phenylpiperidin-1-yl)-3-methylpropylamine using a similar procedure described earlier. It was reacted with 8 (0.620 g, 1.32 mmol) as described earlier to afford the product **10** (0.660 g, 72%). ¹H NMR (CDCl₃): δ 0.90 (d, J = 6.6 Hz, 3 H), 1.18 (t, J = 7.0 Hz, 3 H), 1.42–1.53 (m, 1 H), 1.60-1.68 (m, 2 H), 1.78-1.86 (m, 1 H), 1.92-2.02 (m, 1 H), 2.18-2.26 (m, 1 H), 2.40-2.70 (m, 6 H), 2.80-2.88 (m, 1 H), 3.24–3.38 (m, 2 H), 3.61 (s, 3 H), 5.12 (ABq, $d_A = 5.05$, d_B = 5.20, J = 12.3 Hz, 2 H), 6.68 (s, 1 H), 6.72 (s, 1 H), 6.97-7.37 (m, 14 H), 8.76 (t, J = 4.2 Hz, 1 H).

(b) (+)-5-Carboxamido-6-(3,4-difluorophenyl)-4-ethyl-1-{*N*-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)-3methylpropyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (14). Prepared from 10 (0.660 g, 0.958 mmol) using a similar procedure described earlier to afford the product (0.293 g, 51%). ¹H NMR (CDCl₃): δ 0.90 (d, J = 6.6 Hz, 3 H), 1.20 (t, J = 7.0 Hz, 3 H), 1.46–1.72 (m, 3 H), 1.79–1.88 (m, 1 H), 1.92–2.02 (m, 1 H), 2.16–2.26 (m, m, 1 H), 2.40–2.80 (m, 7 H), 3.26–3.40 (m, 2 H), 3.60 (s, 3 H), 5.40 (br s, 2 H), 6.46 (s, 1 H), 6.72 (s, 1 H), 7.06–7.38 (m, 8 H), 8.78 (t, J = 5 Hz, 1 H). HCl salt Mp: 218–221 °C. [α]_D = + 80.0 (c = 0.25, MeOH). Anal. ($C_{32}H_{38}N_5O_5F_2Cl^{-}0.9$ H₂O) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{N-[5-(4methoxycarbonyl-4-phenyl)piperidin-1-yl)pentyl]carboxamido}-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (18). (a) 3-(5-Chloropentyl)-6-(3,4-difluorophenyl)-5methoxycarbonyl-4-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine (17). To a solution of 6-(3,4-difluorophenyl)-5methoxycarbonyl-4-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine (15; 0.110, 0.426 mmol) in THF (10 mL) and HMPA (1.5 mL, 0.85 mmol) at 0 °C was added NaH (0.014 g, 1.27 mmol) in small portions over 2 min. After stirring at room temperature for 2 min, 1-bromo-5-chloropentane (16; 0.22 mL, 1.70 mmol) was added and the mixture was heated at reflux temperature for 30 min. The reaction mixture was cooled to 0 °C and carefully quenched by the addition of ice water (4 mL). The reaction mixture was concentrated and then partitioned between CH₂Cl₂ (25 mL) and water (5 mL). The organic layer was separated, mixed with aqueous 6 N HCl (3 mL), and stirred at room temperature for 15 min. To this was added saturated aqueous NaHCO₃ solution (15 mL) and the organic layer was separated. It was dried (Na₂SO₄) and the solvent was evaporated. The residue was purified by column chromatography on silica gel (hexanes:EtOAc = 3:2) to yield the product (0.142 g, 91%) as a syrup. ¹H NMR (CDCl₃): δ 1.42–1.79 (m, 7 H), 2.32 (s, 3 H), 2.74–2.83 (m, 1 H), 3.51 (t, *J* = 6.5 Hz, 2 H), 3.69 (s, 3 H), 5.26 (s, 1 H), 7.06–7.20 (m, 3 H), 8.23 (br s, *J* = 5.2 Hz, 1 H).

(b) 4-(3,4-Difluorophenyl)-5-methoxycarbonyl-3-[5-(4methoxycarbonyl-4-phenylpiperidin-1-yl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine (18). To a stirred solution of 17 (0.173 g, 0.447 mmol) in dioxane (20 mL) were added 4-methoxycarbonyl-4-phenylpiperidine (3; 0.196 g, 0.89 mmol) and K_2CO_3 (0.186 g, 1.34 mmol) and the mixture was heated at reflux temperature for 24 h. It was cooled to room temperature, concentrated, and partitioned between EtOAc (25 mL) and water (5 mL). The organic layer was dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography (EtOAc:MeOH, 9:1) to yield the product (0.130 g, 51%) as a colorless oil. ¹H NMR (CDCl₃): δ 1.27–1.52 (m, 8 H), 1.94–2.88 (m, 10 H), 3.66 (s, 9 H), 3.68 (s, 3 H), 3.65–3.68 (m, 3 H), 5.25 (s, 1 H), 7.06-7.38 (m, 9 H), 8.76 (s, 1 H). HCl salt Mp: 140-145 °C. Anal. (C31H38F2N3O5Cl·1.0H2O) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{N-[(4methoxycarbonyl-4-phenylpiperidin-1-yl)ethyl]acetamido}-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (22). (a) 6-(3,4-Difluorophenyl)-1-[(hydroxycarbonyl)methyl]-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,4tetrahydropyrimidine (20). A mixture of 15 (0.296 g, 1.00 mmol), benzyl 2-bromoacetate (0.229 g, 1.00 mmol), K₂CO₃ (600 mg), and KI (30 mg) in DMF (20 mL) was stirred and heated at 50-55 °C for 12 h. The mixture was cooled, poured into ice–water (150 mL), and extracted with ether (3 \times 20 mL). The combined organic layers were dried (Na₂SO₄) and concentrated. The residue was redissolved in THF (10 mL), mixed with aqueous 6 N HCl (3 mL), and stirred for 2 h. Solvent was evaporated and the residue was purified by column chromatography on silica gel (1:1 EtOAc/hexanes) to obtain the benzyl ester 19 (0.32 g, 75%). This intermediate (200 mg, 0.465 mmol) was dissolved in methanol/water (4:1, 15 mL) and mixed with Pearlman's catalyst (20 mg). The resulting suspension was hydrogenated at 100 psi for 4 h. TLC analysis confirmed the disappearance of the starting material. The catalyst was removed by filtration and the solvent was evaporated from the filtrate. The residue was dried under vacuum and used in the next step (0.135 g).

(b) 2-[4-Methoxycarbonyl-4-phenylpiperidin-1-yl]ethylamine (21). A mixture of 4-methoxycarbonyl-4-phenylpiperidine (3; 1.2 g, 7.76 mmol), 2-bromoethylamine hydrobromide (3.28 g, 16 mmol), K₂CO₃ (2.7 g, 19.5 mmol), and KI (0.648 g, 3.9 mmol) in 1,4-dioxane (25 mL) was heated at reflux temperature for 36 h. Dioxane was evaporated under reduced pressure, and the residue was treated with ice-cold 6 N NaOH (400 mL) and extracted with CH_2Cl_2 (4 \times 120 mL). The combined organic layers were dried (K₂CO₃) and concentrated. The residue was purified by column chromatography on silica gel using CHCl₃/MeOH/2 M NH₃ in MeOH (20:2:1) as the eluent to afford the product (0.855 g, 42%) as a viscous oil. $^1\mathrm{H}$ NMR (CDCl₃): δ 1.90–2.10 (m, 2 H), 2.10–2.30 (br t, 2 H), 2.40-2.50 (br t, 2 H), 2.50-2.70 (m, 4 H), 2.80-2.90 (m, 4 H), 3.64 (s, 3 H), 7.20-7.45 (m, 5 H).

(c) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{N-[(4-methoxycarbonyl-4-phenylpiperidin-1-yl)ethyl]acetamido}-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (22). A solution of the carboxylic acid 20 (20 mg), EDC (20 mg), DMAP (20 mg), and amine 21 (20 mg) in CH₂Cl₂ (10 mL) was stirred at room temperature for 24 h. The reaction mixture was diluted with more CH₂Cl₂ (20 mL) and washed with aqueous NH_4Cl solution (4 \times 10 mL). The organic layer was dried (Na_2SO_4) and concentrated. The residue was purified by preparative thin-layer chromatography on silica gel using CHCl₃/MeOH/2 M NH₃ in MeOH (20:2:1) as the eluent (25 mg). MH⁺ 585. [α]_D = + 108 (c = 0.5, MeOH). ¹H NMR (CDCl₃): δ 1.80–2.00 (m, 2 H), 2.05–2.15 (m, 2 H), 2.20 (s, 3 H), 2.40–2.44 (m, 2 H), 2.50–2.65 (m, 2 H), 2.70–2.95 (m, 2 H), 3.20–3.40 (m, 2 H), 3.418, 3.473, 4.301, 4.355 (ABq, 2 H), 3.59 (s, 3 H), 3.64 (s, 3 H), 5.30 (s, 1 H), 6.60 (br t, 1 H, NH), 7.04–7.41 (m, 8 H), 7.95 (br s, 1 H, NH). HCl salt Mp: 247–250 °C. Anal. (C₃₀H₃₄N₆O₆F₂Cl) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{N-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido]-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (27). (a) 1-Benzyl-4-[4-methoxycarbonyl-4-phenylpiperidin-1yl]piperidine (24). A mixture of 4-methoxycarbonyl-4-phenylpiperidine (3; 6.50 g, 29.6 mmol), 1-benzyl-4-piperidone (23; 5.62 g, 29.6 mmol), and p-toluenesulfonic acid (100 mg) in toluene (80 mL) was heated at reflux temperature for 14 h while the water formed was trapped using a Dean-Stark apparatus. Solvent was evaporated and the residue was dissolved in methanol (200 mL) and cooled to 0-5 °C. Sodium cyanoborohydride (1.86 g, 29.6 mmol) was added in portions in about 30 min and the mixture was stirred for 12 h. Solvent was evaporated and the residue was treated with ice-water (400 g). The mixture was extracted with CH_2Cl_2 (4 \times 50 mL) and the combined extracts were washed with brine (3 \times 100 mL). The organic layer was dried (Na₂SO₄) and concentrated. The residue was crystallized from 2-propanol and hexanes to get product 24 as white crystals (8.50 g, 73%). Mp: 112-113 °C. ¹H NMR (CDCl₃): δ 1.50–1.60 (m, 2 H), 1.68–1.80 (m, 2 H), 1.85–2.00 (m, 4 H), 2.20–2.35 (m, 3 H), 2.50–2.60 (m, 2 H), 2.85-2.95 (br t, 4 H), 3.45 (s, 2 H), 3.60 (s, 3 H), 7.20-7.40 (m, 10 H).

(b) 4-[4-Methoxycarbonyl-4-phenylpiperidin-1-yl]piperidine (25). 1-Benzyl-4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidine (24; 3.92 g, 10 mmol) was dissolved in a freshly prepared solution of formic acid in methanol (4.4%, 200 mL) and cooled to 0 °C. To this was added 10% Pd-C (1.0 g) cautiously in about 45 min and the mixture was stirred and allowed to warm to room temperature. After 8 h, the catalyst was removed by filtration and washed with more methanol (50 mL). Solvent was evaporated from the filtrate, the residue was treated with ice-cold NaOH (6 N, 50 mL), and the mixture was extracted with ether (4 \times 50 mL). Evaporation of solvent from the combined dried (Na₂SO₄) extracts left the product as a viscous oil (2.90 g, 96%). The ¹H NMR analysis confirmed the product to be pure and was used in the next step. ¹H NMR (CDCl₃): δ 1.30–1.50 (m, 2 H), 1.70–1.80 (m, 2 H), 1.85–2.00 (m, 2 H), 2.25-2.40 (m, 3 H), 2.50-2.65 (m, 4 H), 2.85-2.95 (br d, 2 H), 3.05-3.15 (br d, 2 H), 3.60 (s, 3 H), 7.20-7.40 (m, 5 H).

(c) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{N-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1yl)carboxamido}-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (27). Prepared from 26 (138 mg, 0.30 mmol) and 25 (100 mg, 0.33 mmol) using a similar procedure described earlier (108 mg, 59%). ¹H NMR (CD₃OD): δ 1.70–1.85 (m, 2 H), 2.05–2.30 (m, 4 H), 2.80–3.00 (m, 4 H), 3.00–3.20 (br t, 2 H), 3.35–3.45 (m, 1 H), 3.55–3.65 (m, 4 H), 3.67 (s, 3 H), 3.69 (s, 3 H), 5.80 (s, 1 H), 7.00–7.60 (m, 8 H). Anal. (C₃₃H₃₇N₄O₆F₂-Cl+0.4CH₂Cl₂) C, H, N.

(+)-6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1yl)carboxamido}-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (36). (a) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (32). To a well-stirred mixture of methyl 4-methoxyacetoacetate (28; 50 g, 0.351 mol), 3,4-difluorobenzaldehyde (30; 51.39 g, 0.351 mol), and urea (29; 31.64 g, 0.527 mol) in THF (300 mL) at room temperature were added copper(I) oxide (5.06 g, 0.035 mol) and acetic acid (2.05 mL) sequentially followed by dropwise addition of boron trifluoride-diethyl etherate (56 mL, 0.456 mole). The mixture was stirred and heated at reflux temperature for 8 h, whereupon TLC (1/1 EtOAc/hexanes) indicated completion of the reaction. It was cooled and poured into a mixture of ice (500 g) and NaHCO₃ (100 g) and the resulting mixture was filtered through Celite. The Celite pad was washed with CH₂Cl₂ (400 mL). The organic layer was separated from the filtrate and the aqueous layer was extracted with more CH₂Cl₂ (3 × 300 mL). The combined organic extracts were dried (Na₂SO₄) and the solvent was evaporated. The crude product was purified by flash column chromatography on silica gel (50% EtOAc in hexanes, then EtOAc) to give the product **32** as a pale yellow foam, which on trituration with hexanes became a white powder (103 g, 94%). ¹H NMR (CDCl₃): δ 3.47 (s, 3 H), 3.65 (s, 3 H), 4.65 (s, 2 H), 5.39 (s, 1 H), 6.60 (br s, 1 H, NH), 7.00–7.20 (m, 3 H), 7.72 (br s, 1 H, NH).

(b) (+)-6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine [(+)-32]. The 32 was resolved by chiral HPLC [Chiralcel OD 20 × 250 mm #369-703-30604]; λ 254 nm; hexanes/ethanol, 90/10; 85 mg/injection; retention time of the desired enantiomer: 16.94 min. The first enantiomer peak to elute gave (+)-32 (40– 42 wt % isolation of the desired enantiomer from the racemate). [α]_D = +84 (c = 0.5, CHCl₃).

(c) (+)-6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4methoxymethyl-1-[(4-nitrophenyloxy)carbonyl]-2-oxo-1,2,3,6-tetrahydropyrimidine (34). To a solution of (+)-32 (1.98 g, 6.34 mmol) in anhydrous THF (20 mL) at −78 °C under argon atmosphere was added a solution of LiHMDS in THF (1.0 M, 18.0 mL, 18.0 mmol) over 2-3 min and the mixture was stirred for 10 min. This solution was added over 6 min via a cannula to a stirred solution of 4-nitrophenyl chloroformate (4.47 g, 22.2 mmol) in THF (20 mL) at -78 °C. The stirring was continued for 10 min and the mixture was poured onto ice (50 g) and extracted with $CHCl_3$ (2 \times 50 mL). The combined extracts were dried (Na₂SO₄) and the solvent was evaporated. The residue was purified by flash column chromatography using hexanes/EtOAc (4:1 to 3.5:1) as eluent. The product was obtained as a yellow syrup, which on trituration with hexanes became a white powder (2.4 g, 79%). ¹H NMR (CDCl₃): δ 3.52 (s, 3 H), 3.74 (s, 3 H), 4.65–4.80 (q, J = 16.5Hz, 2 H), 6.32 (s, 1 H), 7.10–7.30 (m, 4 H), 7.36 (d, J = 9 Hz, 2 H), 8.27 (d, J = 9 Hz, 2 H).

(d) (+)-6-(3,4-Difluorophenyl)-5-methoxycarbonyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-4-methoxymethyl-2-oxo-1,2,3,6tetrahydropyrimidine (36). Prepared from 34 (120 mg, 0.25 mmol) and the amine 25 (80 mg, 0.27 mmol) using a similar procedure described earlier to afford the product (0.146 g, 91%). ¹H NMR (CD₃OD): δ 1.70–1.80 (m, 2 H), 2.00–2.20 (m, 4 H), 2.80–3.00 (m, 4 H), 3.00–3.20 (br t, 2 H), 3.35–3.45 (m, 1 H), 3.40 (s, 3 H), 3.55–3.65 (m, 4 H), 3.60 (s, 3 H), 3.72 (s, 3 H), 4.60 (ABq, J = 12 Hz, 2 H), 5.75 (s, 1 H), 7.05–7.50 (m, 8 H). Anal. (C₃₃H₃₉N₄O₇F₂Cl·0.4CH₂Cl₂) C, H, N.

(+)-5-Methoxycarbonyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro-6-(3,4,5-trifluorophenyl)pyrimidine (37). (a) 5-Methoxycarbonyl-4-methoxymethyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4,5-trifluorophenyl)pyrimidine (33). Prepared from 3,4,5-trifluorobenzaldehyde (37.0 g, 230 mmol), methyl 4-methoxyacetoacetate (33.6 g, 230 mmol), and urea (20.7 g, 345 mmol) using a similar procedure described earlier. The product was obtained as a white powder (72.9 g, 94%).

(b) (+)-5-Methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro-6-(3,4,5-trifluorophenyl)pyrimidine [(+)-33]. The racemic 33 was resolved by chiral HPLC [Chiralcel OD 20 × 250 mm #369-703-30604]; λ 254 nm; hexanes/ethanol, 90/10; 80 mg/injection; retention time of the desired enantiomer: 16.94 min. The first enantiomer peak to elute gave (+)-33 (40-42 wt % isolation of the desired enantiomer from the racemate). [α]_D = +86.8 (c = 0.5, CHCl₃).

(c) (+)-5-Methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro-6-(3,4,5-trifluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (35). Prepared from (+)- **33** (1.34 g, 4.05 mmol), LiHMDS (4.5 mL, 1.0 M), and 4-nitrophenyl chloroformate (0.804 g, 4 mmol) using a similar procedure described earlier (1.75 g, 85%). $[\alpha]_D = +86.8$ (c = 0.5, CHCl₃). ¹H NMR (CDCl₃): δ 3.53 (s, 3 H), 3.75 (s, 3 H), 4.65–4.80 (q, J = 16.5 Hz, 2 H), 6.29 (s, 1 H), 7.03–7.08 (m, 2 H), 7.38 (d, J = 9 Hz, 2 H), 8.29 (d, J = 9 Hz, 2 H).

(d) (+)-5-Methoxycarbonyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro-6-(3,4,5-trifluorophenyl)pyrimidine (37). Prepared from 35 (50 mg, 0.101 mmol) and the amine 25 (50 mg, 0.165 mmol) using a similar procedure described earlier to afford the product (66 mg, 99%). [α] = +135 (c = 0.65, MeOH). HCl salt Mp: 178– 181 °C. ¹H NMR (CD₃OD): δ 1.70–1.80 (m, 2 H), 2.00–2.20 (m, 4 H), 2.80–3.00 (m, 4 H), 3.00–3.20 (br t, 2 H), 3.35–3.45 (m, 1 H), 3.40 (s, 3 H), 3.55–3.65 (m, 4 H), 3.60 (s, 3 H), 3.72 (s, 3 H), 4.60 (ABq, J = 12 Hz, 2 H), 5.75 (s, 1 H), 7.05–7.50 (m, 7 H). Anal. (C₃₃H₃₈ClF₃N₄O₇.0.4CH₂Cl₂) C, H, N.

(+)-5-Carboxamido-6-(2,4-difluorophenyl)-4-ethyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (41). (a) (+)-5-Benzyloxycarbonyl-6-(2,4-difluorophenyl)-4-ethyl-1-{N-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-2-oxo-1,2,3,6tetrahydropyrimidine (39). To a solution of 38² (140 mg, 0.254 mmol) and 25 (82 mg, 0.272 mmol) in THF (15 mL) was added K₂CO₃ (0.50 g). The resulting suspension was stirred over 10 h at room temperature before filtered. The filtrate was cooled in an ice bath and 6 N HCl (5 mL) was added. The resulting mixture was warmed to room temperature and stirred for 30 min before adjusting the pH to 8 with aqueous 10% NaOH. The mixture was extracted with EtOAc (50 mL). The organic layer was washed with 10% K₂CO₃ (20 mL) and brine (50 mL), dried (K₂CO₃), and concentrated and the residue was purified by column chromatography on silica gel (CHCl₃/ MeOH/2 N NH₃ in MeOH = 100:3:1) to afford the desired product (184 mg, 97%). $[\alpha] = +72$ (c = 0.58, CHCl₃). ¹H NMR (CDCl₃): δ 1.19 (t, J = 7 Hz, 3 H), 1.55–1.70 (m, 4 H), 1.80– 1.94 (m, 2 H), 2.10-2.38 (m, 4 H), 2.48-2.60 (m, 2 H), 2.62-2.85 (m, 4 H), 3.61 (s, 3 H), 4.86-5.06 (m, 2 H), 6.64-6.74 (m, 2 H), 7.03-7.12 (m, 2 H), 7.22-7.38 (m, 10 H).

(b) (+)-6-(2,4-Difluorophenyl)-4-ethyl-1-{*N*-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine-5-carboxylic Acid (40). To a solution of **39** (166 mg, 0.240 mmol) in MeOH (10 mL) was added 10% Pd-C (25 mg) in portions in about 10 min. The resulting suspension was hydrogenated at 100 psi for 6 h at room temperature. The mixture was filtered through a pad of Celite and the filtrate was concentrated to leave the product as a white solid (135 mg, 92%).²⁵ The product was used in the next step without further purification. [α] = + 96 (c = 0.75, 20% MeOH-CHCl₃).

(c) (+)-5-Carboxamido-6-(2,4-difluorophenyl)-4-ethyl-1-{N-(4-[4-methoxycarbonyl-4-phenylpiperidin-1-yl]piperidin-1-yl)carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (41). To a solution of 40 (115 mg, 0.188 mmol) in CH₂Cl₂ (30 mL) were added EDC (107 mg, 0.564 mmol) and DMAP (69 mg, 0.564 mmol). The resulting mixture was stirred at room temperature for 1 h. Then NH₃ gas was bubbled through the solution for 3 h. The resulting mixture was stirred over 2 days before washed with aqueous NH₄Cl (30 mL \times 3) and brine $(3 \times 30 \text{ mL})$. The organic phase was dried (K_2CO_3) , concentrated, and purified by column chromatography (CHCl₃/ MeOH/2 M NH₃ in MeOH = 100:4:1) to afford the product as a white solid (80 mg, 70%). $[\alpha] = +107^{\circ}$ (c = 0.88, CHCl₃). ¹H NMR (CDCl₃): δ 1.05-1.25 (m, 6 H), 1.65-1.98 (m, 4 H), 2.06-2.38 (m, 4 H), 2.46-2.80 (m, 6 H), 3.10-3.33 (m, 2 H), 3.61 (s, 3 H), 6.53 (s, 1 H), 6.75-6.95 (m, 3 H), 7.20-7.38 (m, 5 H), 7.60-7.70 (m, 1 H), 11.20-11.30 (m, 1 H). HCl salt Mp: 122-124 °C. Anal. (C₃₂H₃₈N₅O₅ClF₂·0.25CHCl₃) C, H, N.

6-(3,4-Difluorophenyl)-1-{*N*-[3-[4-(6'-hydroxyphenylisonipecotic acid lactone)-1-yl]propyl]carboxamido}-5methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (46). (a) *N*-(*tert*-Butoxycarbonylaminopropyl)- **4-(6'-hydroxyphenyl)isonipecotic Acid Lactone.** To a stirred solution of the 4-phenylisonipecotic acid lactone¹⁵ (**42a**; 0.736 g, 3.64 mmol) in dioxane (20 mL) were added *N*-(*tert*-butoxycarbonyl)-3-bromopropylamine (**43**; 0.953 g, 4 mmol) and K₂CO₃ (1.00 g, 7.28 mmol) and the mixture was heated at reflux temperature for 24 h. The reaction mixture was cooled to room temperature, concentrated, and partitioned between CHCl₃ (40 mL) and water (5 mL). The organic layer was dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography (EtOAc:MeOH, 9:1) to yield the product as a colorless oil (0.574 g, 44%). ¹H NMR (CDCl₃): δ 1.46 (s, 9 H), 1.73 (t, *J* = 6.3 Hz, 2 H), 2.00–2.05 (m, 4 H), 2.59 (t, *J* = 6.3 Hz, 2 H), 2.70–2.84 (m, 4 H), 3.24 (d, *J* = 5.8 Hz, 2 H), 5.59 (br s, 1 H), 7.12 (t, *J* = 8.1 Hz), 7.28–7.33 (m, 2 H).

(b) *N*-(3-Aminopropyl)-4-(6'-hydroxyphenyl)isonipecotic Acid Lactone (45a). To *N*-(*tert*-butoxycarbonylaminopropyl)-4-(6'-hydroxyphenyl)isonipecotic acid lactone (0.254 g, 0.707 mmol) in CH_2Cl_2 (5 mL) was added trifluoroacetic acid (1 mL) and the solution stirred at room temperature for 1 h. It was concentrated, neutralized with aqueous 10% KOH solution and extracted with CH_2Cl_2 (25 mL). The organic layer was dried (Na₂SO₄) and concentrated to give 0.183 g (100%) of the product which was used as such in the next step.

(c) 6-(3,4-Difluorophenyl)-1-{*N*-[3-[4-(6'-hydroxyphenylisonipecotic acid lactone)-1-yl] propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (46). Prepared from amine 45a (0.054 g, 0.207 mmol) and 26 (0.080 g, 0.173 mmol) using a similar procedure described earlier to give the product (0.055 g, 56%) as a syrup. ¹H NMR (CDCl₃): δ 1.63–1.76 (m, 4 H), 2.14–2.19 (m, 2 H), 2.40–2.48 (m, 7 H), 2.86 (d, J = 11 Hz, 2 H), 3.30–3.41 (m, 2 H), 3.68 (s, 3 H), 6.68 (s, 1 H), 7.01–7.17 (m, 3 H), 7.38 (d, J = 7.4 Hz, 1 H), 7.49 (t, J = 7.4 Hz, 1 H), 7.63 (t, J = 7.4 Hz, 1 H), 7.83 (d, J = 7.4 Hz, 1 H), 8.83 (t, J = 5.4 Hz, 1 H). HCl salt Mp: 173–176 °C. Anal. (C₂₇H₃₁F₂N₄O₆Cl·1.0H₂O) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2oxo-1-{N-[[spiro(isobenzofuran-1(3*H*),4'-piperidin)-3-one]-1-propyl]carboxamido}-1,2,3,6-tetrahydropyrimidine (47). (a) *N*-(*tert*-Butoxycarbonylaminopropyl)spiro-(isobenzofuran-1(3*H*),4'-piperidin)-3-one. Prepared from spiro(isobenzofuran-1(3*H*),4'-piperidin)-3-one¹⁵ (42b; 0.393 g, 19.3 mmol) and *N*-(*tert*-butoxycarbonyl)-3-bromopropylamine (0.506 g, 21.2 mmol) using a similar procedure described earlier to give the required product as a colorless oil (0.438 g, 63%). ¹H NMR (CDCl₃): δ 1.46 (s, 9 H), 1.70–1.76 (m, 4 H), 2.19–2.23 (m, 2 H), 2.47–2.57 (m, 4 H), 2.95 (d, *J* = 11 Hz, 2 H), 3.24 (d, *J* = 5.89 Hz, 2 H), 5.50 (s, 1 H), 7.40 (d, *J* = 7.35 Hz, 1 H), 7.55 (t, *J* = 7.35 Hz, 1 H), 7.68 (d, *J* = 7.35 Hz, 1 H), 7.89 (d, *J* = 7.36 Hz, 1 H).

(b) *N*-**(3-Aminopropyl)spiro(isobenzofuran-1(3***H***),4'-piperidin)-3-one (45b).** Prepared from *N*-(*tert*-butoxycarbonyl-aminopropyl)spiro(isobenzofuran-1(3*H*),4'-piperidin)-3-one (0.438 g, 12.1 mmol) and trifluoroacetic acid (1 mL) using a similar procedure described earlier to give the amine **45b** (0.150 g, 47%) which was used as such in the next step.

(c) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1-{*N*-[[spiro(isobenzofuran-1(3*H*),4'-piperidin)-3-one]-1-propyl]carboxamido}-1,2,3,6-tetrahydropyrimidine (47). Prepared from 26 (0.060 g, 0.129 mmol) and 45b (0.037 g, 0.142 mmol) using a similar procedure described earlier to give the product (0.072 g, 97%) as a syrup. ¹H NMR (CDCl₃): δ 1.63–1.76 (m, 4 H), 2.14–2.19 (m, 2 H), 2.40–2.48 (m, 7 H), 2.86 (d, *J* = 11 Hz, 2 H), 3.30–3.41 (m, 2 H), 3.68 (s, 3 H), 6.68 (s, 1 H), 7.01–7.17 (m, 3 H), 7.38 (d, *J* = 7.4 Hz, 1 H), 7.49 (t, *J* = 7.4 Hz, 1 H), 7.63 (t, *J* = 7.4 Hz, 1 H), 7.83 (d, *J* = 7.4 Hz, 1 H), 8.83 (t, *J* = 5.4 Hz, 1 H). HCl salt Mp: 185–187 °C. Anal. (C₂₉H₃₂F₂N₅O₆Cl₂·1.0H₂O) C, H, N.

6-(3,4-Difluorophenyl)-1-{*N*-[[4-(isobenzofuranyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (48). (a) *N*-(*tert*-Butoxycarbonylaminopropyl)-4-(isobenzofuranyl)piperidine. Prepared from 4-(isobenzofuranyl)piperidine¹⁵ (**42c**; 0.566 g, 3.27 mmol) and *N*-(*tert*-butoxycarbonyl)-3-bromopropylamine (0.772 g, 3.27 mmol) using a similar procedure described earlier to give the product (0.856 g, 79%). ¹H NMR (CDCl₃): δ 1.45 (s, 9 H), 1.63–2.04 (m, 6 H), 2.33–2.52 (m, 4 H), 2.87 (d, *J* = 11.0 Hz, 2 H), 3.20 (br s, 2 H), 5.07 (s, 2 H), 5.6 (br s, 1 H), 7.13–7.28 (m, 4 H).

(b) *N*-(Aminopropyl)-4-(isobenzofuranyl)piperidine (45c). Prepared from 42 (0.50 g, 1.51 mmol) using a similar procedure described earlier (0.340 g, 98%).

(c) 6-(3,4-Difluorophenyl)-1-{N-[[4-(isobenzofuranyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (48). Prepared from 26 (0.052 g, 0.112 mmol) and 45c (0.032 g, 0.123 mmol) using a similar procedure described earlier (0.040 g, 64%). ¹H NMR (CDCl₃): δ 1.73–1.78 (m, 7 H), 1.93–2.04 (m, 2 H), 2.33–2.48 (m, 6 H), 2.83 (d, J = 11.8 Hz, 2 H), 3.35– 3.41 (m, 2 H), 3.71 (s, 3 H), 5.06 (s, 2 H), 6.75 (s, 1 H), 7.04– 7.26 (m, 7 H), 8.82 (t, J = 5.1 Hz, 1 H). HCl salt Mp: 178–182 °C. Anal. (C₂₉H₃₄F₂N₄O₅Cl₂·0.6H₂O) C, H, N.

6-(3,4-Difluorophenyl)-1-{*N*-[[4-(dihydroindenyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (49). (a) *N*-(*tert*-Butoxycarbonylaminopropyl)-4-(dihydroindenyl)-piperidine. Prepared from 4-(dihydroindenyl)piperidine¹⁵ (42d; 0.790 g, 4.22 mmol) and *N*-(*tert*-butoxycarbonyl)-3-bromopropylamine (1.10 g, 4.64 mmol) using a similar procedure described earlier (0.886 g, 61%). ¹H NMR (CDCl₃): δ 1.46 (s, 9 H), 1.55 (d, *J* = 11.3 Hz, 2 H), 1.69 (t, *J* = 6.3 Hz, 2 H), 1.88–2.47 (m, 6 H), 2.47 (t, *J* = 6.3 Hz, 2 H), 2.88 (t, *J* = 3.3 Hz, 4 H), 3.23 (d, *J* = 5.6 Hz, 2 H), 5.85 (br s, 1 H), 7.18 (s, 4 H).

(b) *N*-(3-Aminopropyl)-4-(dihydroindenyl)piperidine (45d). Prepared from 42d (0.180 g, 0.52 mmol) using a similar procedure described earlier (0.156 g, 100%).

(c) 6-(3,4-Difluorophenyl)-1-{N-[[4-(dihydroindenyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (49). Prepared from 26 (0.050 g, 0.108 mmol) and *N*-(3-aminopropyl)-4-(dihydroindenyl)piperidine (45d; 0.053 g, 0.216 mmol) using a similar procedure described earlier (0.060 g, 100%). ¹H NMR (CDCl₃): δ 1.52 (d, *J* = 13.2 Hz, 2 H), 1.70–2.07 (m, 8 H), 2.12 (t, *J* = 10.3 Hz, 2 H), 2.42 (s, 4 H), 2.86–2.91 (m, 3 H), 3.32–3.43 (m, 2 H), 3.72 (s, 3 H), 6.71 (s, 1 H), 7.04–7.19 (m, 7 H), 8.82 (t, *J* = 5.2 Hz, 1 H). HCl salt Mp: 150–153 °C. Anal. (C₃₀H₃₆F₂N₄O₆Cl₂) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2oxo-1-{N-[[spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one]-1-propyl]carboxamido}-1,2,3,6-tetrahydropyrimidine (50). (a) *N*-(*tert*-Butoxycarbonylaminopropyl)spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one. Prepared from spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one¹⁵ (42e; 0.242 g, 1.11 mmol) and *N*-(*tert*-butoxycarbonyl)-3-bromopropylamine (0.291 g, 1.22 mmol) using a similar procedure described earlier (0.237 g, 57%). ¹H NMR (CDCl₃): δ 1.39 (s, 9 H), 1.65 (t, *J* = 6.47 Hz, 2 H), 1.96 (d, *J* = 15.6 Hz, 2 H), 2.22 (t, *J* = 2.5 Hz, 2 H), 2.46-2.56 (m, 4 H), 2.80-2.84 (m, 2 H), 3.17-3.18 (m, 2 H), 3.73 (s, 2 H), 5.58 (br s, 1 H), 7.12 (s, 1 H), 7.22-7.27 (m, 3 H).

(b) *N*-(Aminopropyl)spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one (45e). Prepared from *N*-(*tert*-butoxycarbonylaminopropyl)spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one (0.237 g, 0.72 mmol) using a similar procedure described earlier (0.150 g, 87%).

(c) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1-{*N*-[[spiro(isobenzopyran-1(3*H*),4'-piperidin)-3-one]-1-propyl}]arboxamido}-1,2,3,6-tetrahydropyrimidine (50). Prepared from 26 (0.077 g, 0.166 mmol) and *N*-(aminopropyl)spiro(isobenzopyran-1(3*H*),4'-piperidin)-3one (45e; 0.050 g, 0.183 mmol) using a similar procedure described earlier (0.072 g, 72%). ¹H NMR (CDCl₃): δ 1.72 (t, J = 6.1 Hz, 2 H), 1.93 (d, J = 16.2 Hz, 2 H), 2.19 (t, J = 6.9Hz, 2 H), 2.38 (s, 3 H), 2.43–2.55 (m, 4 H), 2.81 (s, 2 H), 3.28– 3.42 (m, 2 H), 3.67 (s, 3 H), 3.73 (s, 3 H), 6.66 (s, 1 H), 7.0– 7.25 (m, 4 H), 7.28 (s, 2 H), 7.45 (s, 1 H), 8.82 (t, J = 5.2 Hz, 1 H). HCl salt Mp: 165–168 °C. Anal. $(C_{30}H_{34}F_2N_4O_6Cl_2{}^{\star}2.0H_2O)$ C, H, N.

1-{*N*-[[4-(Benzopyranyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (51). (a) [4-(Benzopyranyl)piperidin-1-yl]propylamine (45f). Prepared using a similar procedure described for 45e.

(b) 1-{*N*-[[4-(Benzopyranyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (51). Prepared from 26 (0.048 g, 0.103 mmol) and [4-(benzopyranyl)piperidin-1-yl]propylamine (45f; 0.053 g, 0.207 mmol) using a similar procedure described earlier (0.066 g, 100%). $[\alpha]_D = +69$ (c = 1.32, CHCl₃). ¹H NMR (CDCl₃): δ 1.70–2.06 (m, 6 H), 2.43–2.47 (m, 7 H), 2.75–2.82 (m, 4 H), 3.33–3.42 (m, 2 H), 3.72 (s, 3 H), 3.89 (t, J = 5.1 Hz, 2 H), 6.71 (s, 1 H), 7.05–7.21 (m, 7 H), 8.85 (t, J = 5.2 Hz, 1 H). HCl salt Mp: 150–152 °C. Anal. (C₃₀H₃₆F₂N₄O₅Cl₂·2.5H₂O) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2oxo-1-{N-[[4-(tetralinyl)piperidin-1-yl]propyl]carboxamido}-1,2,3,6-tetrahydropyrimidine (52). (a) *N*-(tert-Butoxycarbonylaminopropyl)-4-(tetralinyl)piperidine. Prepared from 4-(tetralinyl)piperidine¹⁵ (42g; 0.512 g, 2.56 mmol) and *N*-(tert-butoxycarbonyl)-3-bromopropylamine (0.666 g, 2.80 mmol) using a similar procedure described earlier (0.258 g, 28%). ¹H NMR (CDCl₃): δ 1.47 (s, 9 H), 1.59–2.83 (m, 18 H), 3.23–3.25 (m, 2 H), 6.27 (br s, 1 H), 7.05–7.14 (m, 2 H).

(b) *N*-(Aminopropyl)-4-(tetralinyl)piperidine (45g). Prepared from *N*-(*tert*-butoxycarbonylaminopropyl)-4-(tetralinyl)-piperidine (0.258 g, 0.720 mmol) using a similar procedure described earlier (0.183 g, 99%).

(c) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydro-1-{N-[[4-(tetralinyl)piperidin-1-yl]propyl]carboxamido}pyrimidine (52). Prepared from 26 (0.025 g, 0.054 mmol) and N-(aminopropyl)-4-(tetralinyl)-piperidine (45g; 0.029 g, 0.010 mmol) using a similar procedure described earlier (0.026 g, 87%). ¹H NMR (CDCl₃): δ 1.57 (d, J = 13.2 Hz, 2 H), 1.73–2.27 (m, 9 H), 2.41 (s, 6 H), 2.75 (s, 4 H), 3.31–3.45 (m, 2 H), 3.71 (s, 3 H), 6.70 (s, 1 H), 7.00–7.39 (m, 6 H), 7.48 (d, J = 7.7 Hz, 1 H), 8.83 (s, 1 H). HCl salt Mp: 148–152 °C. Anal. (C₃₁H₃₈F₂N₄O₅Cl₂·1.0H₂O) C, H, N.

6-(3,4-Difluorophenyl)-1-{*N*-[**3-(4,4-diphenylpiperidin-1-yl)propyl]carboxamido**}-5-methoxycarbonyl-4-methyl-**2-oxo-1,2,3,6-tetrahydropyrimidine (56).** Prepared from **26** (231 mg, 0.500 mmol) and 3-(4,4-diphenylpiperidin-1-yl)propylamine³ (220 mg, 0.750 mmol) using a similar procedure described earlier (286 mg, 93%). HCl salt Mp: 161–164 °C. ¹H NMR (CDCl₃): α 1.25 (m, 4 H), 1.68 (q, *J* = 7.6 Hz, 2 H), 2.39 (s, 3 H), 2.60–2.20 (m, 6 H), 3.60–3.20 (m, 3 H), 3.69 (s, 3 H), 6.67 (s, 1 H), 7.80 (b, 1 H), 8.81 (m, 1 H). Anal. (C₃₄H₃₇F₂N₄O₄Cl·0.25C₆H₁₄) C, H, N.

General Procedure for the Preparation of Compounds 57–60. General Procedure for the Preparation of 4,4-Diarylpiperidines 54a–54d. A mixture of 4-aryl-4-hydroxypiperidine (**53a–53d**; 0.50 g), substituted benzene (3.0 mL), and AlCl₃ (1.0 g) was stirred at room temperature for 3 days. The reaction mixture was treated with ice–water (10 mL) and diluted with *tert*-butyl methyl ether; the resulting hydrochloride salt formed was filtered, washed with water and ether, dried, and used in the next step after spectral characterization. Full experimental details for **54e** will be given below due to the unexpected product (**54e**) obtained from the Friedel–Crafts reaction of 4-hydroxy-4-(4-methylphenyl)piperidine and *m*xylene. Other examples of this highly unusual reaction will be reported in due course.

Bis-4-(3,5-dimethylphenyl)piperidime Hydrochloride (54e). To a turbid solution of 4-hydroxy-4-(4-methylphenyl)piperidine (3.14 mmol, 0.60 g) in *m*-xylene (10 mL) at room temperature was added anhydrous aluminum chloride (4.32 mmol, 0.58 g) in one portion (isotherm was observed) and the resulting suspension was allowed to stir overnight under argon atmosphere. The dark solution was then poured over an ice– water bath and was stirred vigorously for 1 h. The resulting off-white solid was filtered through a sintered glass funnel and washed with 50 mL of CH_2CL_2 and 50 mL of Et_2O . The off-white powder was dried under vacuum and used in the next step without further purification (0.36 g, 35% yield). Mass spectrum (ESMS, MH⁺) was consistent with the proposed structure. The regiochemistry of the methyl groups was assigned based on the symmetrical nature of the ¹H NMR spectrum and lack of splitting for the aromatic protons. The ¹H NMR spectrum was also recorded in DMSO-*d*₆ and was identical to the one in CD₃OD. Mp: = 246–252 °C. ¹H NMR (CD₃OD): δ 2.24 (s, 12 H), 2.59 (br s, 4 H), 3.17 (br s, 4 H), 6.82 (s, 2 H), 6.91 (s, 4 H). Mass spectrum (ESMS, MH⁺, low res.): 293 (100%). Anal. Calcd for C₂₁H₂₈ClN.0.5CH₂Cl₂: C, 69.35; H, 7.85; N, 3.76. Found: C, 69.76; H, 7.61; N, 3.99.

1-(3-Bromopropylcarbamoyl)-6-(3,4-difluorophenyl)-5methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (55). To a well-stirred solution of 26 (4.1 g, 9.1 mmol) in THF (20 mL) was added aqueous HCl (10%, 10 mL) at room temperature and the resulting solution was stirred overnight. THF was evaporated under reduced pressure and the resulting residue was extracted with EtOAc (3×20 mL), washed with brine (10 mL), and then dried (Na₂SO₄). The solvent was evaporated under reduced pressure to obtain (+)-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-1-[(4-nitrophenyloxy)carbonyl]-2-oxo-1,2,3,6-tetrahydropyrimidine as a viscous oil (3.8 g). It was redissolved in THF (20 mL) and mixed with 3-bromopropylamine hydrobromide (2.33 g, 10.8 g) and NaHCO₃ (1.81 g, 21.5 mmol) and the resulting suspension was stirred at room temperature overnight. Solvent was evaporated under reduced pressure and the resulting residue was treated with water (10 mL) and then extracted with EtOAc (3 \times 20 mL). The EtOAc extracts were combined and dried (Na₂SO₄) and the solvent was evaporated to obtain the product (3.28 g, 83%). ¹H NMR (CDCl₃): δ 2.05-2.15 (m, 2 H), 2.43 (s, 3 H), 3.40-3.56 (m, 4 H), 3.72 (s, 3 H), 6.69 (s, 1 H), 7.08-7.27 (m, 3 H), 7.57 (br s, 1 H), 8.84 (br t, 1 H). Anal. (C₁₇H₁₈N₃O₄F₂Br) C, H, N.

Reaction of Piperidines 54a–54d and (3-Bromopropyl)carbamoyldihydropyrimidinone 55. A mixture of **55** (45 mg, 0.10 mmol), 4,4-diarylpiperidine hydrochloride (0.10 mmol), and diisopropylethylamine (0.5 mL) in dioxane (2.0 mL) was heated at reflux temperature for 2 days. The mixture was cooled and the crude product was purified by preparative thinlayer chromatography on silica gel using 2-3% MeOH in EtOAc as eluent. The products were converted to their HCl salts by treatment with 1 N HCl in ether.

1-{[3-[Bis-4-(4-chlorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (57). (a) Bis-4-(4-chlorophenyl)piperidine Hydrochloride (54a). Prepared from 4-(4-chlorophenyl)-4-hydroxypiperidine and chlorobenzene. Yield: 92%. ¹H NMR (CD₃OD): δ 7.60–7.30 (m, 8 H), 3.18 (m, 4 H), 2.65 (m, 4 H). Anal. (C₁₇H₁₈N₁Cl₃) C, H, N.

(b) 1-{[3-[Bis-4-(4-chlorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (57). Yield: 71%. ¹H NMR (CDCl₃): δ 8.83 (t, J = 7 Hz, 1 H), 7.40–6.90 (m, 12 H), 6.03 (br s, 1 H), 3.72 (s, 3 H), 3.60–3.20 (m, 2 H), 2.76 (m, 2 H), 2.58 (m, 4 H), 2.39 (s, 3 H), 1.85 (q, J = 7.6 Hz, 2 H), 1.42 (m, 4 H). Anal. (C₃₄H₃₅Cl₃N₄F₂O₄·1.0 Et₂O) C, H, N.

6-(3,4-Difluorophenyl)-1-{[3-[4-bis(4-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (58). (a) Bis-4-(4-fluorophenyl)piperidine Hydrochloride (54b). Prepared from 4-(4-fluorophenyl)-4-hydroxypiperidine and fluorobenzene. Yield: 69%. ¹H NMR (CD₃OD): \delta 7.40–7.05 (m, 8 H), 3.19 (m, 4 H), 2.65 (m, 4 H).

(b) 6-(3,4-Difluorophenyl)-1-{[3-[4-bis(4-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (58). Yield: 80%. ¹H NMR (CDCl₃): δ 8.81 (m, 1 H), 7.80 (b, 1 H), 7.30– 6.80 (m, 11 H), 6.67 (s, 1 H), 3.69 (s, 3 H), 3.60–3.20 (m, 3 H), 2.60–2.20 (m, 6 H), 2.39 (s, 3 H), 1.68 (q, J = 7.6 Hz, 2 H), 1.25 (m, 4 H). Anal. (C₃₄H₃₅F₄N₄O₄Cl·1H₂O) C, H, N.

6-(3,4-Difluorophenyl)-1-{N-[3-[4-(4-methylphenyl)-4-(2-methylphenyl)piperidin-1-yl]propyl]carboxamido}-5methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (59). (a) 4-(4-Methylphenyl)-4-(2-methylphenyl)piperidine Hydrochloride (54c). Yield: 99%. MS: 266 (M + 1, 100%). Anal. (C₁₉H₂₄NCl·0.15CH₂Cl₂) C, H, N.

(b) 6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-1-{*N*-[3-[4-(4-methylphenyl)-4-(2-methylphenyl)piperidin-1-yl]propyl]carboxamido}-2-oxo-1,2,3,6-tetrahydropyrimidine (59). Yield: 64%. HCl salt Mp: 143–147 °C. $[\alpha]_D$ = +79.8° (c = 0.25, MeOH). Anal. ($C_{37}H_{44}N_4O_4F_2Cl\cdot0.5CH_2$ -Cl₂) C, H, N.

6-(3,4-Difluorophenyl)-1-{[3-[4-bis(3,5-dimethylphenyl)-piperidin-1-yl]propyl]carboxamido}-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (60). Yield: 77%. Mp: 176–180 °C. [α] = +93.6 (c = 0.28, MeOH). ¹H NMR (CDCl₃): δ 8 (m, 2 H), 2.25 (s, 12 H), 2.30 (t, J = 6.9 Hz, 2 H), 2.37–2.42 (m, 7 H), 2.47 (br s, 4 H), 3.22–3.41 (m, 2 H), 3.71 (s, 3 H), 6.68 (s, 1 H), 6.77 (s, 2 H), 6.85 (s, 4 H), 7.01–7.20 (m, 4 H), 8.77 (t, J = 5.4 Hz, 1 H). Anal. (C₃₈H₄₅F₂N₄O₄Cl·0.7CH₂Cl₂) C, H, N.

1-{N-[3-[4-Acetoxy-4-phenylpiperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (66). (a) N-Benzyloxycarbonyl-3-(4-hydroxy-4-phenylpiperidin-1-yl)propylamine (63). A mixture of 4-hydroxy-4-phenylpiperidine (61; 5.00 g, 0.028 mol), N-benzyloxycarbonyl-3-bromopropylamine (62; 8.45 g, 0.031 mol), and K₂CO₃ (7.795 g, 0.0564 mol) in acetone (200 mL) was stirred and heated at reflux temperature for 12 h. Acetone was evaporated at reduced pressure, and the residue was treated with ice-cold water (400 mL) and extracted with CH_2Cl_2 (4 \times 120 mL). Solvent was evaporated from the combined dried (Na_2SO_4) extracts and the residue was found to be pure product (9.50 g, 91%) by TLC and ¹H NMR. It was used in the next step as such without any further purification.

(b) *N*-Benzyloxycarbonyl-3-(4-acetoxy-4-phenylpiperidin-1-yl)propylamine. To a solution of **63** (0.50 g, 1.36 mmol) in THF (20 mL) at 0 °C was added NaH (60% suspension in paraffin, 65 mg, 1.63 mmol) and the mixture was stirred for 1.5 h. To this suspension was added acetyl bromide (0.12 mL, 1.63 mmol) and the mixture was stirred at 0 °C for 30 min and at room temperature for 3 h. Solvent was evaporated and the residue was mixed with CH_2Cl_2 (100 mL) and washed with water (2×20 mL). The organic layer was dried (Na₂SO₄) and concentrated to obtain the product as a viscous oil (0.485 g, 87%). The ¹H NMR showed this product to be pure and it was used in the next step without any further purification. ¹H NMR (CDCl₃): δ 1.82–1.92 (m, 4 H), 2.01 (s, 3 H), 2.24–2.33 (m, 2 H), 2.42–2.50 (m, 4 H), 2.78–2.84 (m, 2 H), 3.24 (m, 2 H), 5.05 (s, 2 H), 6.00 (br s, 1 H), 7.28–7.38 (m, 10 H).

(c) 3-(4-Acetoxy-4-phenylpiperidin-1-yl)propylamine (65a). A mixture of *N*-benzyloxycarbonyl-3-(4-acetoxy-4-phenylpiperidin-1-yl)propylamine (3.0 g, 7.3 mmol) and 10% Pd–C (0.3 g) in 1.0 M NH₃ in MeOH (50 mL) was hydrogenated at 70 psi at room temperature for 4 h. The catalyst was removed by filtration and the solvent was evaporated to leave the product as a viscous oil (2.01 g, 99%). ¹H NMR showed it to be pure product and was used in the next step without any purification. ¹H NMR (CDCl₃): δ 1.70–1.82 (m, 4 H), 2.01 (s, 3 H), 2.25–2.35 (m, 2 H), 2.42–2.55 (m, 4 H), 2.82–2.92 (m, 4 H), 7.18–7.36 (m, 5 H).

(d) 1-{*N*-[3-[4-Acetoxy-4-phenylpiperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (66). Prepared from 26 (0.295 g, 0.64 mmol) and 65a (0.23 g, 0.832 mmol) using a similar procedure described earlier (0.210 g, 55%). ¹H NMR (CDCl₃): δ 1.70-1.78 (m, 2 H), 2.02 (s, 3 H), 2.22-2.30 (m, 2 H), 2.34 (s, 3 H), 2.36-2.44 (m, 4 H), 2.72-2.80 (m, 2 H), 3.24-3.40 (m, 2 H), 3.68 (s, 3 H), 6.66 (s, 1 H), 7.02-7.32 (m, 8 H), 8.80 (t, J = 7 Hz, 1 H). HCl salt Mp: 95-97 °C. Anal. (C₃₀H₃₅N₄O₆F₂Cl·0.8CHCl₃) C, H, N.

4-(3,4-Difluorophenyl)-6-methyl-2-oxo-3-{(4-methoxy-4-phenylpiperidin-1-yl)propyl}-5-methoxycarbonyl-1,2,3,4tetrahydropyrimidine (67). To a solution of 26 (0.06 g, 0.129 mmol) in dry CH₂Cl₂ (10 mL) was added 3-(4-methoxy-4phenylpiperidin-1-yl)propylamine⁵ (65b; 0.072 g, 0.259 mmol) and the solution was stirred at room temperature for 24 h. The reaction mixture was stirred for another 1 h after addition of 6 N HCl (2 mL). It was basified with 10% aqueous KOH solution (pH = 9) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic layer was dried (Na₂SO₄) and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc:MeOH, 9:1) to obtain the product as a syrup (0.056 g, 77%). ¹H NMR (CDCl₃): δ 1.76–2.00 (m, 4 H), 2.39–2.44 (m, 6 H), 2.72–2.85 (m, 2 H), 2.95 (s, 3 H), 3.30 (m, 2 H), 3.71 (s, 3 H), 6.70 (s, 1 H), 7.04–7.41 (m, 8 H), 8.83 (t, J = 5.2 Hz, 1 H). HCl salt Mp: 170-174 °C. Anal. (C29H36F2N4O5Cl· 1.3H₂O) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-2oxo-1-{*N***-[3-(4-phenylpiperidin-1-yl)propyl]carboxamido}-1,2,3,6-tetrahydropyrimidine (68).** Prepared from **26** (100 mg, 0.217 mmol) and 3-(4-phenylpiperidin-1-yl)propylamine **(65c**; 95 mg, 0.433 mmol) using a similar procedure described earlier (105 mg, 89%). ¹H NMR (CDCl₃): δ 1.76–1.90 (m, 6 H), 2.02–2.25 (m, 2 H), 2.45 (s, 3 H), 2.46–2.58 (m, 2 H), 3.02– 3.10 (m, 2 H), 3.36–3.46 (m, 2 H), 3.68 (s, 3 H), 3.98 (s, 3 H), 6.60 (s, 1 H), 7.02–7.38 (m, 8 H). HCl salt Mp: 133–136 °C. Anal. (C₂₈H₃₃F₂N₄O₄Cl·0.2CH₂Cl₂) C, H, N.

(+)-1-{*N*-[[4-Cyano-4-phenylpiperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (69). Prepared from **26** (30 mg, 0.067 mmol) and **65d** (30 mg, 0.123 mmol) using a similar procedure described earlier to afford the product (30 mg, 81%). (M + 1): 552. ¹H NMR (CDCl₃): δ 1.70–1.78 (m, 2 H), 2.04–2.16 (m, 2 H), 2.34 (s, 3 H), 2.35–2.43 (m, 2 H), 2.44–2.52 (m, 4 H), 2.98–3.02 (m, 2 H), 3.32–3.42 (m, 2 H), 3.64 (s, 3 H), 6.68 (s, 1 H), 7.02–7.49 (m, 8 H), 8.84 (t, J=7 Hz, 1 H). HCl salt Mp: 140–143 °C. Anal. (C₂₉H₃₂F₂N₅O₄Cl) C, H, N.

6-(3,4-Difluorophenyl)-5-methoxycarbonyl-4-methyl-1-{*N*-[**3-(4-methyl-4-phenylpiperidin-1-yl)propyl]carboxamido**}-**2-oxo-1,2,3,6-tetrahydropyrimidine (70).** Prepared from **26** and **65e**⁵ using a similar procedure described earlier in 0.16 mmol scale. Yield: 71%. $[\alpha]_D = + 92.7$ (c = 0.18, MeOH). ¹H NMR (CDCl₃): δ 1.21 (s, 3 H), 1.69–1.87 (m, 6 H), 2.09–2.15 (m, 2 H), 2.31 (t, J = 7.5 Hz, 2 H), 2.32–2.50 (m, 4 H), 2.40 (s, 3 H), 3.30–3.36 (m, 2 H), 3.71 (s, 3 H), 6.69 (s, 1 H), 7.02–7.38 (m, 9 H), 8.78 (t, J = 5.7 Hz, 1 H). The HCl salt was hygroscopic. Anal. ($C_{29}H_{35}N_4O_4F_2Cl\cdot0.7CH_2Cl_2$) C, H, N.

(+)-5-Carboxamido-1-{*N*-[3-(4-cyano-4-phenylpiperidin-1-yl)propyl]carboxamido}-6-(2,4-difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (73). (a) (+)-5-(Benzyloxycarbonyl)-1-{N-[3-(4-cyano-4-phenylpiperidin-1yl)propyl]carboxamido}-6-(2,4-difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (71). A mixture of (+)-5-(benzyloxycarbonyl)-6-(2,4-difluorophenyl)-1,6-dihydro-4ethyl-2-methoxy-1-[(4-nitrophenyloxy)carbonyl]pyrimidine² (38; 6.50 g, 11.81 mmol) and 3-[4-cyano-4-phenylpiperidin-1-yl]propylamine⁵ (65d; 3.60 g, 15.36 mmol) in THF (500 mL) was stirred at room temperature for 18 h. It was cooled to 0 °C and aqueous 10% HCl (2 mL) was added and stirred for 2 h. The mixture was washed with aqueous NaOH (0.5 N, 30 mL) and dried (Na₂SO₄) and the solvent evaporated. The residue was purified by column chromatography on silica gel using CHCl₃/MeOH/2 M NH₃ in MeOH (100/2/1) as the eluent to obtain product 71 as a white foamy solid (7.05 g, 93%). ¹H NMR ($\hat{C}DCl_3$): δ 1.16 (t, J = 7.5 Hz, 3 H), 1.64–1.68 (m, 2 H), 1.99-2.08 (m, 4 H), 2.34-2.42 (m, 4 H), 2.60-2.80 (m, 2 H), 2.89 (br d, J = 12 Hz, 2 H), 3.18–3.40 (m, 2 H), 5.26 (q, J =11 Hz, 2 H), 6.60-7.45 (m, 14 H), 8.86 (br t, 1 H, NH).

(b) 1-{N-[3-(4-Cyano-4-phenylpiperidin-1-yl)propyl]carboxamido}-6-(2,4-difluorophenyl)-4-ethyl-1,2,3,6-tetrahydro-2-oxopyrimidine-5-carboxylic Acid (72). To a suspension of 10% Pd-C (2.1 g) in MeOH (100 mL) and H₂O (20 mL) was added a solution of 71 (7.55 g, 11.2 mL) in methanol (100 mL) and the mixture was hydrogenated at 80 psi for 14 h.²⁵ The black suspension was filtered through a pad of Celite and washed thoroughly with MeOH (2.0 L) and MeOH/CHCl₃ (1:2, 200 mL). Solvent was evaporated from the combined filtrate to leave the product **72** as a white solid (6.06 g, 98%). It was used in the next step without further purification.

(c) (+)-5-Carboxamido-1-{*N*-[3-(4-cyano-4-phenylpiperidin-1-yl)propyl]carboxamido}-6-(2,4-difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (73). A mixture of 72 (6.30 g, 11.2 mmol), EDC (4.29 g, 22.4 mmol, 2 equiv), and DMAP (3.41 g, 27.95 mmol, 2.5 equiv) in anhydrous CH₂Cl₂ (400 mL) was stirred at room temperature for 2 h. To this was added 40% aqueous NH₃ (6.13 g, 5 equiv) and the stirring continued for 12 h. The mixture was diluted with CH₂- Cl_2 (200 mL) and washed with saturated aqueous NH_4Cl solution (3 \times 200 mL). Solvent was evaporated from the dried (Na₂SO₄) organic layer and the residue was purified by column chromatography on silica gel using CHCl₃-MeOH-2 M NH₃ in methanol (100/2/1) as the eluent to obtain the desired product as a white powder (5.45 g, 87%). ¹H NMR (CDCl₃): δ 1.18 (t, J = 7.6 Hz, 3 H), 1.66–1.68 (m, 4 H), 2.04–2.09 (m, 4 H), 2.36-2.44 (m, 4 H), 2.60-2.78 (m, 2 H), 2.91 (br d, 2 H), 3.20-3.40 (m, 2 H), 5.70 (br s, 2 H), 6.55 (s, 1 H), 6.64-6.84 (m, 2 H), 7.20-7.55 (m, 6 H), 8.88 (br t, 1 H, NH). HCl salt Mp: 196–197 °C. $[\alpha]_D = +126$ (c = 0.505, 1:1 CHCl₃/MeOH). Anal. (C₂₉H₃₃N₆O₃F₂Cl) C, H, N.

(+)-1-{*N*-[[4-Cyano-4-phenylpiperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (79). To a solution of 34 (223 mg, 46.8 mmol) in CH₂Cl₂ (20 mL) was added 3-(4-cyano-4-phenylpiperidin-1-yl)propylamine (65d; 137 mg, 56 mmol). The resulting mixture was stirred at room temperature for 2 h and the solvent evaporated. The residue was purified by column chromatography on silica gel (CHCl₃/MeOH/2 M NH₃ in MeOH = 100:12:6) to afford the desired product (230 mg, 82%). [α]_D = 129° (c = 0.625, CHCl₃). ¹H NMR (CDCl₃) δ 1.70–1.78 (m, 2 H), 2.00–2.20 (m, 4 H), 2.38–2.50 (m, 4 H), 2.94–3.00 (m, 2 H), 3.25–3.45 (m, 2 H), 3.45 (s, 3 H), 3.67 (s, 3 H), 4.65 (s, 2 H), 6.65 (s, 1 H), 6.97–7.45 (m, 8 H), 7.65 (br s, 1 H), 8.92 (t, J = 7 Hz, 1 H). HCl salt Mp: 118–119 °C. Anal. (C₃₀H₃₅F₂N₅O₅Cl·1.2H₂O) C, H, N.

1-{[3-[4-Cyano-4-(2-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (80). (a) 4-Cyano-4-(2-fluorophenyl)piperidine (76a). To a solution of 2-fluorophenylacetonitrile (75a; 1.35 g, 10 mmol) and N-tert-butoxycarbonyl-bis(2-chloroethyl)amine (74; 2.42 g, 10 mmol) in DMF (30 mL) at 0 °C was added NaH (0.76 g, 95%, 30 mmol) carefully over 10 min. The resulting suspension was stirred and heated at 60 °C for 24 h. The reaction mixture was cooled and quenched with ice-water (100 mL) and the mixture was extracted with EtOAc (50 mL \times 3). The combined organic layers were dried (MgSO₄) and concentrated and the residue was purified by column chromatography on silica gel (20% EtOAc/hexanes) to yield the BOC-protected piperidine. It was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (10 mL). The resulting mixture was stirred for 3 h and the solvent was evaporated. The residue was treated with aqueous 1 N NaOH, adjusted the pH to 10, and extracted with CH₂Cl₂ (3 \times 30 mL). The organic extracts were dried (K₂CO₃), concentrated, and purified by column chromatography on silica gel (80% EtOAc in hexanes) to yield the desired piperidine 76a (933 mg, 30%).

(b) 1-*N*-(3-Aminopropyl)-4-cyano-4-(2-fluorophenyl)piperidine (78a). To a solution of 4-cyano-4-(2-fluorophenyl)piperidine (76a; 933 mg, 3.00 mmol) and *N*-(3-bromopropyl)phthalimide (965 mg, 3.60 mmol) in DMF (20 mL) were added K_2CO_3 (2.00 g) and KI (100 mg). The resulting suspension was stirred vigorously at 80 °C for 12 h and then quenched with ice-water (60 mL). The mixture was extracted with EtOAc (3 \times 50 mL). The combined organic layers was dried (MgSO₄), concentrated, and purified by column chromatography on silica gel (30% EtOAc in hexanes) to yield the phthalimide-protected intermediate. It was dissolved in MeOH (40 mL) and treated with hydrazine (3.0 mL). The resulting mixture was heated at reflux temperature overnight. The white solid formed was filtered and the solvent was evaporated from the filtrate. The residue was purified by column chromatography on silica gel using CHCl₃:MeOH:2 M NH₃ in MeOH (100:8:4) as the eluent to yield the desired amine **78a** (607 mg, 55%) as a colorless oil.

(c) 1-{[3-[4-Cyano-4-(2-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (80). Prepared from 34 (25 mg, 0.052 mmol) and 1-N-(3-aminopropyl)-4-cyano-4-(2-fluorophenyl)piperidine (78a; 26 mg, 0.10 mmol) using a similar procedure described earlier (25 mg, 81%). ¹H NMR (CDCl₃): δ 1.70–1.78 (m, 2 H), 2.00– 2.08 (m, 4 H), 2.38–2.50 (m, 4 H), 2.94–3.00 (m, 2 H), 3.30– 3.47 (m, 2 H), 3.48 (s, 3 H), 3.70 (s, 3 H), 4.68 (s, 2 H), 6.67 (s, 1 H), 6.97–7.45 (m, 7 H), 7.69 (br s, 1 H), 8.97 (t, J = 7 Hz, 1 H). HCl salt Mp: 132–135 °C. Anal. (C₃₀H₃₃F₃N₅O₅Cl·0.5CH₂-Cl₂) C, H, N.

(+)-1-{[3-[4-Cyano-4-(3-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (81). (a) 4-Cyano-4-(3-fluorophenyl)piperidine (76b). Prepared from 3-fluorophenylacetonitrile (1.35 g, 10.0 mmol), *N-tert*-butoxycarbonyl-bis(2-chloroethyl)amine (2.42 g, 10.0 mmol), and NaH (0.76 g, 95%, 30 mmol) using a similar procedure described earlier (995 mg, 32%).

(b) 1-*N*-(3-Aminopropyl)-4-cyano-4-(3-fluorophenyl)piperidine (78b). Prepared from 76b (995 mg, 3.20 mmol) and *N*-(3-bromopropyl)phthalimide (965 mg, 3.60 mmol) using a similar procedure described earlier (colorless oil, 640 mg, 58%).

(c) (+)-1-{[3-[4-Cyano-4-(3-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (81). Prepared from 34 (25 mg, 0.052 mmol) and 78b (26 mg, 0.10 mmol) using a similar procedure described earlier (25 mg, 81%). ¹H NMR (CDCl₃): δ 1.70–1.78 (m, 2 H), 2.00–2.08 (m, 4 H), 2.38–2.50 (m, 4 H), 2.94–3.00 (m, 2 H), 3.30–3.47 (m, 2 H), 3.48 (s, 3 H), 3.70 (s, 3 H), 4.68 (s, 2 H), 6.67 (s, 1 H), 6.97–7.45 (m, 7 H), 7.69 (br s, 1 H), 8.97 (t, J= 7 Hz, 1 H). HCl salt Mp: 124–127 °C. Anal. (C₃₀H₃₃F₃N₅O₅-Cl¹0.5CH₂Cl₂) C, H, N.

(+)-1-{*N*-[3-[4-Cyano-4-(4-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (82). (a) 4-Cyano-4-(4-fluorophenyl)piperidine (76c). Prepared from 4-fluorophenylacetonitrile (1.35 g, 10.0 mmol), *N*-tert-butoxycarbonyl-bis(2-chloroethyl)amine (2.42 g, 10.0 mmol), and NaH (0.76 g, 95%, 30 mmol) using a similar procedure described earlier (2.0 g, 64%).

(b) 1-*N*-(3-Aminopropyl)-4-cyano-4-(4-fluorophenyl)piperidine (78c). Prepared from 76c (1.55 g, 5.0 mmol) and *N*-(3-bromopropy)phthalimide (1.480 g, 5.50 mmol) using a similar procedure described earlier (colorless oil, 1.10 g, 64%).

(c) (+)-1-{*N*-[3-[4-Cyano-4-(4-fluorophenyl)piperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (82). Prepared from 34 (25 mg, 0.052 mmol) and 78c (26 mg, 0.10 mmol) using a similar procedure described earlier (30 mg, 96%). ¹H NMR (CDCl₃): δ 1.74 (m, 2 H), 2.06 (m, 4 H), 2.49 (m, 4 H), 3.00 (m, 2 H), 3.40 (m, 2 H), 3.48 (s, 3 H), 3.70 (s, 3 H), 4.67 (s, 2 H), 6.67 (s, 1 H), 7.08 (m, 4 H), 7.18 (m, 1 H), 7.48 (m, 2 H), 7.67 (bs, 1 H), 8.97 (bt, 1 H). HCl salt, white solid; Mp: 103-106 °C. CIMS: $m/e = 600 (MH^+)$. [α]_D = 106.0 (c = 0.205, MeOH). Anal. (C₃₀H₃₃F₃N₅O₅Cl·0.9CHCl₃) C, H, N.

(+)-1-{*N*-[3-[4-Methyl-4-phenylpiperidin-1-yl]propyl]carboxamido}-6-(3,4-difluorophenyl)-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (83). Prepared from 34 and amine 65e using a similar procedure described earlier. Yield: 0.12 g (81%). $[\alpha]_D = + 82.1$ (c = 0.31, MeOH). ¹H NMR (CDCl₃): δ 1.14 (s, 3 H), 1.61–1.72 (m, 4 H), 2.03–2.08 (m, 2 H), 2.25 (t, J = 7.2 Hz, 2 H), 2.30–2.42 (m, 4 H), 3.19–3.31 (m, 2 H), 3.40 (s, 3 H), 3.63 (s, 3 H), 4.60 (s, 2 H), 6.60 (s, 1 H), 6.97–7.29 (m, 8 H), 7.63 (br s, 1 H), 8.78 (t, J = 5.7 Hz, 1 H). The HCl salt was hygroscopic. Anal. ($C_{30}H_{37}N_4O_5F_2Cl$ ·1.0CH₂Cl₂) C, H, N.

Acknowledgment. We thank Mr. Yong Zheng for the technical assistance in cell culture and membrane preparation and Mr. Boshan Li and Mr. Vincent Jorgensen for the technical assistance in radioligand displacement assays. We also thank Dr. John Zgombick for providing us with the serotonin cross-reactivity data.

References

- Presented in parts: (a) Murali Dhar, T. G.; Tyagarajan, S.; Marzabadi, M. R.; Nagarathnam, D.; Miao, S. W.; Lagu, B.; Wong, W. C.; Chiu, G.; Fang, J.; Forray, C.; Gluchowski, C. Design, Synthesis, and Evaluation of Dihydropyrimidinones as Alpha-1a Selective Antagonists: 3. Modification of the Piperidine Moiety. 214th ACS National Meeting, Las Vegas, NV, Sept 7–11, 1997; MEDI #84. (b) Nagarathnam, D.; Wong, W. C.; Lagu, B.; Miao, S. W.; Tyagarajan, S.; Sun, W.; Zhang, J.; Shen, Q.; Tian, D.; Tang, C.; Murali Dhar, T. G.; Marzabadi, M. R.; Forray, C.; Gluchowski, C.; Chang, R. S. L.; Broten, T.; Schorn, T. W.; Chen, T. B.; O'Malley, S.; Ransom, R.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K.; Zhang, K.; Gilbert, J.; Pettibone, D. J.; Freidinger, R. M. Design, Synthesis, and Evaluation of Dihydropyrimidinones as Alpha-1a Selective Antagonists: 6. Synthesis and Structure-Activity Relationship of SNAP 6552 and Analogues. 215th ACS National Meeting, Dallas, TX, Mar 29– Apr 2, 1998; MEDI #66. (c) Marzabadi, M. R.; Lagu, B.; Tian, D.; Wong, W. C.; Nagarathnam, D.; Chiu, G.; Miao, S. W.; Zhang, F.; Sun, W.; Forray, C.; Gluchowski, C.; Chang, R.; Broten, T.; Schorn, T. W.; Chen, T. B.; O'Malley, S. O.; Ransom, R.; Schneck, K.; Bendesky, R.; Harrel, C. M.; Vyas, K.; Zhang, K.; Gilbert, J.; Pettibone, D. J.; Freidinger, R. M. Design, Synthesis, and Evaluation of Dihydropyrimidinones as Alpha-1a Selective Antagonists: 7. Modification of the Diarylpiperidine Moiety. 215th ACS National Meeting, Dallas, TX, Mar 29–Apr 2, 1998; MEDI #67.
- MED1 #07.
 (2) Please see the preceding paper: Nagarathnam, D.; Miao, S. W.; Chiu, G.; Fang, J.; Lagu, B.; Murali Dhar, T. G.; Zhang, J.; Tyagarajan, S.; Marzabadi, M. R.; Zhang, F.; Wong, W. C.; Sun, W.; Tian, D.; Wetzel, J. M.; Forray, C.; Chang, R. S. L.; Broten, T. P.; Schorn, T. W.; Chen, T. B.; O'Malley, S.; Ransom, R.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Gluchowski, C. Design and Synthesis of Novel a_{1a} Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones. J. Med. Chem. 1999, 42, 4764-4777.
- (3) Wetzel, J. M.; Miao, S. W.; Forray, C.; Borden, L. A.; Branchek, T. A.; Gluchowski, C. Discovery of α_{1a}-Adrenergic Receptor Antagonists Based on the L-Type Ca²⁺ Channel Antagonist Niguldipine. *J. Med. Chem.* **1995**, *38*, 1579–1581.
 (4) Wong, W. C.; Chiu, G.; Wetzel, J. M.; Marzabadi, M. R.; Nagrathang D.; Warg, D.; Carg, L.; Miao, S. W.; Hang, X.;
- (4) Wong, W. C.; Chiu, G.; Wetzel, J. M.; Marzabadi, M. R.; Nagarathnam, D.; Wang, D.; Fang, J.; Miao, S. W.; Hong, X.; Forray, C.; Vaysse, P. J.-J.; Branchek, T. A.; Gluchowski, C.; Tang, R.; Lepor, H. Identification of a Dihydropyridine as a Potent α_{1a} Adrenoceptor Selective Antagonist that Inhibits Phenylephrine-Induced Contraction of the Human Prostate. *J. Med. Chem.* **1998**, *41*, 2643–2650.
- (5) Nagarathnam, D.; Wetzel, J. M.; Miao, S. W.; Marzabadi, M. R.; Chiu, G.; Wong, W. C.; Hong, X.; Fang, J.; Forray, C.; Branchek, T. A.; Heydorn, W. E.; Chang, R. S. L.; Broten, T.; Schorn, T. W.; Gluchowski, C. Design and Synthesis of Novel α_{1a} Adrenoceptor Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia. *J. Med. Chem.* **1998**, *41*, 5320–5333.
- (6) Hieble, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, Jr., R. R. International Union of Pharmacology X. Recommendation of Nomenclature of α₁-Adrenoceptors: Consensus Update. *Pharmacol. Rev.* **1995**, *47*, 267–270.
- (7) Geller, J.; Kirschenbaum, A.; Lepor, H.; Levine, A. C. Therapeutic Controversies: Clinical Treatment of Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab. 1995, 80, 745–747.

- (8) Garraway, W. M.; Collins, G. N.; Lee, R. J. High Prevalence of Benign Prostatic Hypertrophy in the Community. *Lancet* 1991, *338*, 469–471.
- (9) Monda, J. M.; Oesterling, J. E. Medical Management of Benign Prostatic Hyperplasia. *Infect. Urol.* **1994**, 47–59.
- (10) Lepor, H. Role of Alpha-Adrenergic Blockers in the Treatment of Benign Prostatic Hyperplasia. *Prostate Suppl.* 1990, *3*, 75– 84.
- (11) Jankegt, R. A.; Chapple, C. R. Efficacy and Safety of the Alpha-1 Blocker Doxazosin in the Treatment of Benign Prostatic Hyperplasia. Analysis of 5 Studies. *Eur. Urol.* **1993**, *24*, 319–325.
- (12) Creese, I.; Snyder, S. H. Receptor Binding and Pharmacological Activity of Opiates in the Guinea-pig Intestine. J. Pharmacol. Exp. Ther. 1975, 194, 205–219.
- (13) Hu, E. H.; Sidler, D. R.; Dolling, U.-H. Unprecedented Catalytic Three Component One-Pot Condensation Reaction: An Efficient Synthesis of 5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2(1H)-ones. J. Org. Chem. **1998**, 63, 3454–3457.
- (14) Parham, W. E.; Edberg, D. E.; Sayed, Y. A.; Thraikill, R. W.; Keyser, G. E.; Neu, M.; Montgomery, W. C.; Jones, L. D. Spiro Piperdines. 1. Synthesis of Spiro[isobenzofuran-1(3*H*), 4'-piperidin]-3-ones, Spiro[isobenzofuran-1(3*H*), 4'-piperidines], and Spiro-[isobenzotetrahydrothiophene-1(3*H*), 4'-piperidines]. J. Org. Chem. **1976**, 41, 2628–2633.
- (15) Chambers, M. S.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Wong, E. H. F. Spiropiperidines as High-Affinity, Selective α Ligands. J. Med. Chem. 1992, 35, 2033– 2039.
- (16) Bolger, G. T.; Gengo, P.; Klockowski, R.; Luchowski, E.; Siegel, H.; Janis, R. A.; Triggle, A. M.; Triggle, D. J. Characterization of Binding of the Ca²⁺ Channel Antagonist, [³H]Nitrendipine, to Guinea-Pig Ileal Smooth Muscle. *J. Pharmacol. Exp. Ther.* **1983**, *225*, 291–309.
- (17) Chang, R. S.; Tran, V. T.; Snyder, S. H. Heterogeneity of Histamine H1-receptors: Species Variations in [³H]Mepyramine Binding of Brain Membranes. *J. Neurochem.* **1979**, *32*, 1653– 1663.
- (18) Gajtkowski, G. A.; Norris, D. B.; Rising, T. J.; Wood, T. P. Specific binding of ³H–Tiotidine to Histamine H2 Receptors in Guineapig Cerebral Cortex. *Nature* **1983**, *304* (5921), 65–67.
- (19) Fargin, A.; Raymond, J.; Lohse, M.; Kobilka, B.; Caron, M.; Lefkowitz, R. The Genomic Clone G-21, Which resembles the α-Adrenergic Receptor Sequence, Encodes the 5-HT1a Receptor. *Nature* **1988**, *335*, 358–360.
- (20) Weinshank, R. L.; Zgombick, J. M.; Macchi, M. J.; Branchek, T. A. Human serotonin 1D receptor is Encoded by a Subfamily of Two Distinct Genes: 5-HT_{1D α} and 5-HT_{1D β}. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, 3630–3634.
- (21) Branchek, T.; Adham, N.; Macchi, M.; Kao, H. T.; Hartig, P. R. [⁹H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [⁹H]-Ketanserin Label Two Affinity States of the Cloned Human 5-Hydroxytryptamine2 Receptor. *Mol. Pharmacol.* **1990**, *38*, 604-609.
- (22) O'Malley, S. S.; Chen. T. B.; Francis, B. E.; Gibson, R. E.; Burns, H. D.; DiSalvo, J.; Bayne, M. L.; Wetzel, J. M.; Nagarathnam, D.; Marzabadi, M. R.; Gluchowski, C.; Chang. R. S. L. Characterization of Specific Binding of [¹²⁵I]L-762,459, A Selective Alpha-1A Radioligand, to Rat and Human Tissues. *Eur. J. Pharmacol.* **1998**, *348*, 287–295.
- (23) Arulaksana, O.; Schild, H. O. Some Quantitative Uses of Drug Antagonists. *Br. J. Pharmacol.* **1959**, *14*, 48–58.
 (24) Lagu, B.; Tian, D.; Nagarathnam, D.; Marzabadi, M. R.; Wong,
- (24) Lagu, B.; Tian, D.; Nagarathnam, D.; Marzabadi, M. R.; Wong, W. C.; Miao, S. W.; Zhang, F.; Sun, W.; Chiu, G.; Fang, J.; Forray, C.; Chang, R. S. L.; Ransom, R. W.; Chen, T. B.; O'Malley, S.; Zhang, S. K.; Vyas, K.; Gluchowski, C. Design and Synthesis of Novel α_{1a} Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side Chains. *J. Med. Chem.* **1999**, *42*, 4794–4803.
- (25) Benzyl protection of the 3,5-carboxyl groups of dihydropyridines has recently been described: Marzabadi, M. R.; Hong, X.; Gluchowski, C. A Double Protection Strategy for the Synthesis of 3,5-Disubstituted Dihydropyridines. *Tetrahedron Lett.* **1998**, *39*, 5293–5296.

JM990201H